

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
22 January 2009 (22.01.2009)

PCT

(10) International Publication Number
WO 2009/010804 A1

(51) International Patent Classification:

C07K 5/08 (2006.01) A61K 38/00 (2006.01)
C07K 5/12 (2006.01) A61K 31/00 (2006.01)

(21) International Application Number:

PCT/GB2008/050585

(22) International Filing Date: 17 July 2008 (17.07.2008)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/961,195 19 July 2007 (19.07.2007) US
60/964,090 9 August 2007 (09.08.2007) US

(71) Applicants (for all designated States except US): **ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A.** [IT/IT]; Via Pontina KM 30.600, 1-00040 Pomezia (Rome) (IT). **MERCK & CO., INC** [US/US]; Sumneytown Pike, P.O. Box 4, West Point, PA 19486 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **LIVERTON, Nigel** [GB/US]; Merck & Co., Inc., Sumneytown Pike, P.O. Box 4, West Point, Pennsylvania 19486 (US). **SUMMA, Vincenzo** [IT/IT]; IRBM, Via Pontina KM 30.600,


1-00040 Pomezia (Rome) (IT). **MCCAULEY, John** [US/US]; Merck & Co., Inc., Sumneytown Pike, P.O. Box 4, West Point, Pennsylvania 19486 (US). **HARPER, Steven** [GB/IT]; IRBM, Via Pontina KM 30.600, 1-00040 Pomezia (Rome) (IT). **BUTCHER, John** [US/US]; Merck & Co., Inc., Sumneytown Pike, P.O. Box 4, West Point, Pennsylvania 19486 (US). **DI FILIPPO, Marcello** [IT/IT]; IRBM, Via Pontina KM 30.600, 1-00040 Pomezia (Rome) (IT). **DI FRANCESCO, Maria Emilia** [IT/IT]; IRBM, Via Pontina KM 30.600, 1-00040 Pomezia (Rome) (IT). **FERRARA, Marco** [IT/IT]; IRBM, Via Pontina KM 30.600, 1-00040 Pomezia (Rome) (IT). **ROMANO, Joseph J.** [US/US]; Merck & Co., Inc., Sumneytown Pike, P.O. Box 4, West Point, Pennsylvania 19486 (US). **RUDD, Michael** [US/US]; Merck & Co., Inc., Sumneytown Pike, P.O. Box 4, West Point, Pennsylvania 19486 (US).

(74) Agent: **ROLLINS, Anthony J.**; European Patent Department, Hertford Road, Hoddesdon, Hertfordshire EN11 9BU (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT,

[Continued on next page]

(54) Title: MACROCYCLIC COMPOUNDS AS ANTIVIRAL AGENTS



(57) Abstract: A class of macrocyclic compounds of formula (I), wherein R^1 , R^3 , R^4 , R^a , R^b , A, Z, Y, X, M, W, n and m are defined herein, that are useful as inhibitors of viral proteases, particularly the hepatitis C virus (HCV) NS3 protease, are provided. Also provided are processes for the synthesis and use of such macrocyclic compounds for treating or preventing HCV infection. Formula (I):

WO 2009/010804 A1



RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

Macrocyclic compounds as antiviral agents

The present invention relates to macrocyclic compounds that are useful as inhibitors of the hepatitis C virus (HCV) NS3 protease, their synthesis, and their use for treating or preventing HCV infection.


Hepatitis C virus (HCV) infection is a major health problem that leads to chronic liver disease, such as cirrhosis and hepatocellular carcinoma, in a substantial number of infected individuals, estimated to be 2-15% of the world's population. According to the World Health Organization, there are more than 170 million infected individuals worldwide, with at least 3 to 4 million people being infected each year. Once infected, about 20% of people clear the virus, but the rest harbor HCV the rest of their lives. Ten to twenty percent of chronically infected individuals eventually develop liver-destroying cirrhosis or cancer. The viral disease is transmitted parenterally by contaminated blood and blood products, contaminated needles, or sexually and vertically from infected mothers or carrier mothers to their offspring.

Current treatments for HCV infection, which are restricted to immunotherapy with recombinant interferon- α alone or in combination with the nucleoside analog ribavirin, are of limited clinical benefit. Moreover, there is no established vaccine for HCV. Consequently, there is an urgent need for improved therapeutic agents that effectively combat chronic HCV infection.

Several virally-encoded enzymes are putative targets for therapeutic intervention, including a metalloprotease (NS2-3), a serine protease (NS3), a helicase (NS3), and an RNA-dependent RNA polymerase (NS5B). The NS3 protease is located in the N-terminal domain of the NS3 protein, and is considered a prime drug target since it is responsible for an intramolecular cleavage at the NS3/4A site and for downstream intermolecular processing at the NS4A/4B, NS4B/5A and NS5A/5B junctions. Previous research has identified classes of peptides, such as hexapeptides as well as tripeptides discussed in U.S. patent applications US2005/0020503, US2004/0229818, and US2004/00229776, showing degrees of activity in inhibiting the NS3 protease. The aim of the present invention is to provide further compounds which exhibit activity against the HCV NS3 protease.

Macrocyclic compounds that exhibit activity against the HCV NS3 protease have already been disclosed in published International patent application nos. WO2006/119061, WO2007/015855 and WO2007/016441 (all Merck & Co., Inc.)

Thus, in one aspect, there is provided the compound of formula (I):



or a pharmaceutically acceptable salt thereof,
wherein:

m is 0, 1, 2 or 3;

5 n is 0, 1 or 2;

R^1 is CO_2R^5 , $\text{CONR}^5\text{SO}_2R^5$, $\text{CONR}^5\text{SO}_2\text{N}(R^5)_2$ or tetrazolyl;

R^a is C_{2-6} alkylene- R^2 ;

R^b is hydrogen;

or R^a and R^b , together with the carbon atom to which they are attached, form a

10 C_{3-6} cycloalkyl group, optionally substituted by R^2 ;

R^2 is C_{1-6} alkyl, C_{2-6} alkenyl or C_{3-8} cycloalkyl, wherein said alkyl, alkenyl or cycloalkyl is optionally substituted with 1 to 3 halo;

R^3 is C_{1-6} alkyl, $(\text{CH}_2)_{0-3}\text{C}_{3-8}$ cycloalkyl, $(\text{CH}_2)_{0-3}$ aryl or $(\text{CH}_2)_{0-3}\text{Het}$, optionally substituted by halo, OR^5 , SR^5 , $\text{N}(R^5)_2$, C_{1-6} alkyl, NO_2 , CN , CF_3 , $\text{NR}^5\text{SO}_2R^5$, $\text{SO}_2\text{N}(R^5)_2$, NHCO_2R^5 ,

15 NHCOR^5 , NHCONHR^5 , CO_2R^5 , C(O)R^5 or $\text{CON}(R^5)_2$;

each R^5 is independently hydrogen, C_{1-6} alkyl or C_{3-8} cycloalkyl;

each W is independently halo, OR^5 , C_{1-6} alkyl, CN , NO_2 , CF_3 , CO_2R^5 , $\text{CON}(R^5)_2$, COR^5 , $\text{NR}^5\text{C(O)R}^5$, aryl or heteroaryl;

Z is O or NR^6 ;

20 R^6 is hydrogen or C_{1-6} alkyl;

Y is C=O , SO_2 or CR^cR^d ;

X is O, NR^e or CR^eR^f ;

R^c , R^d , R^e and R^f are independently hydrogen, halo or C_{1-6} alkyl;

M is C_{4-12} alkylene, C_{4-12} alkenylene or C_{4-12} alkynylene, optionally substituted by C_{1-6} alkyl, $(\text{CH}_2)_{0-3}\text{C}_{3-8}$ cycloalkyl, $(\text{CH}_2)_{0-3}$ aryl, and optionally containing one O or S atom or one NH or NC_{1-6} alkyl group, and optionally spiro-fused to a C_{3-7} cycloalkyl group, and optionally fused to a 3- to 8-membered ring, which ring optionally contains 1 or 2 heteroatoms selected from N, O and S;

ring A is a 8- to 10-membered fused heterobicyclic ring system containing 1 to 4
30 heteroatoms selected from N, O and S, where one and only one of the rings of the heterobicyclic

ring system is fused to a 5- or 6-membered ring, which ring may optionally contain 1 or 2 heteroatoms selected from N, O and S; and

R^4 is halo, hydroxy, C_{1-6} alkyl, C_{1-6} alkoxy, CN, NO_2 , oxo, C_{3-8} cycloalkyl, $N(R^5)_2$, aryl or heteroaryl, optionally substituted by 1 to 8 halo or C_{1-4} alkyl.

5 In one embodiment of the present invention, m is 0 or 1.

In another embodiment of the present invention, n is 0 or 1.

In another embodiment, R^1 is $CONR^5SO_2R^5$ or $CONR^5SO_2N(R^5)_2$ where R^5 is as hereinbefore defined. Preferably, R^1 is $CONR^5SO_2R^5$ where R^5 is as hereinbefore defined. More preferably, R^1 is $CONHSO_2R^5$ where R^5 is as hereinbefore defined. Especially, R^1 is
10 $CONHSO_2-C_{3-8}$ cycloalkyl. More especially, R^1 is $CONHSO_2-C_{3-6}$ cycloalkyl. Most especially, R^1 is $CONHSO_2$ -cyclopropyl.

In another embodiment, R^a is C_{2-5} alkylene- R^2 where R^2 is as hereinbefore defined. Preferably, R^a is C_{2-4} alkylene- R^2 where R^2 is C_{1-6} alkyl, optionally substituted with 1 to 3 halo. More preferably, R^a is C_{2-3} alkylene- R^2 where R^2 is C_{1-4} alkyl, optionally substituted with 1 to 3
15 fluoro or chloro. Most preferably, R^a is ethylene- R^2 where R^2 is C_{1-2} alkyl, optionally substituted by 1 to 3 fluoro. Especially, R^a is ethylene- R^2 where R^2 is difluoromethyl or trifluoromethyl.

In another embodiment, R^a and R^b , together with the carbon atom to which they are attached, form a C_{3-5} cycloalkyl group, optionally substituted by R^2 , where R^2 is C_{1-6} alkyl or C_{2-6} alkenyl. Preferably, R^a and R^b , together with the carbon atom to which they are attached form
20 a C_{3-4} cycloalkyl group, substituted by C_{1-4} alkyl or C_{2-4} alkenyl. More preferably, R^a and R^b , together with the carbon atom to which they are attached, form a cyclopropyl group, substituted by $-CH=CH_2$.

In another embodiment, R^3 is C_{1-6} alkyl, or $(CH_2)_{0-3}C_{3-8}$ cycloalkyl, optionally substituted by halo, OR^5 or C_{1-6} alkyl, where R^5 is as hereinbefore defined. Preferably, R^3 is C_{1-6} alkyl or
25 $(CH_2)_{0-3}C_{3-8}$ cycloalkyl. More preferably, R^3 is C_{1-4} alkyl or C_{3-6} cycloalkyl. Most preferably, R^3 is C_{3-4} alkyl or C_{5-6} cycloalkyl. Especially, R^3 is n butyl, t butyl, cyclopentyl or cyclohexyl.

In another embodiment, each W is independently halo, OR^5 , C_{1-6} alkyl, CN, NO_2 , CF_3 , CO_2R^5 or $CON(R^5)_2$, where R^5 is as hereinbefore defined. Preferably, each W is independently halo, OC_{1-6} alkyl, C_{1-6} alkyl, CN, NO_2 or CF_3 . More preferably, each W is independently OC_{1-4} alkyl
30 or C_{1-4} alkyl. Most preferably, W is OC_{1-2} alkyl or C_{1-2} alkyl. Especially, W is methoxy or methyl.


In another embodiment, Z is O.

In another embodiment Y is C=O.

In another embodiment, X is O or NR^e , where R^e is as hereinbefore defined. Preferably, X is O or NC_{1-4} alkyl. More preferably, X is O or NC_{1-2} alkyl. Most preferably, X is O or NCH_3 .

35 In another embodiment, M is C_{4-10} alkylene, C_{4-10} alkenylene or C_{4-10} alkynylene, optionally substituted by C_{1-6} alkyl or $(CH_2)_{0-3}C_{3-8}$ cycloalkyl, and optionally containing one O or S group or one NH or NC_{1-4} alkyl group, and optionally fused to a 3- to 8-membered carbocyclic ring. Preferably, M is C_{5-8} alkylene or C_{5-8} alkenylene, optionally substituted by C_{1-4} alkyl, and optionally fused to C_{3-6} cycloalkyl. More preferably, M is C_{5-8} alkylene or C_{5-8} alkenylene, optionally


substituted by C₁₋₂alkyl, and optionally fused to C₅₋₆cycloalkyl. Most preferably, M is C₅₋₈alkylene or C₅₋₈alkenylene, optionally substituted by methyl, and optionally fused to cyclopentyl. Examples of suitable M groups are: octylene,




In another embodiment, A is a 9- or 10-membered fused heterobicyclic ring system containing 1 to 3 heteroatoms selected from N and O, where one and only one of the rings of the heterobicyclic system is fused to a 5- or 6-membered ring, which ring may optionally contain 1 or 2 heteroatoms selected from N and S, and which ring is optionally substituted by R⁴, where R⁴ is as hereinbefore defined. Preferably, A is a 9- or 10-membered fused heterobicyclic ring system containing 1 or 2 N atoms, where one and only one of the rings of the heterobicyclic system is fused to a 5- or 6-membered ring, which ring may optionally contain one S atom or two N atoms, and which ring is optionally substituted by R⁴, where R⁴ is as hereinbefore defined. Examples of suitable A groups, optionally substituted by R⁴, are:

15


20





In another embodiment, when R^4 is present, R^4 is halo, hydroxy, C_{1-6} alkyl, C_{1-6} alkoxy, CN, C_{3-8} cycloalkyl or aryl. Preferably, R^4 is fluoro, chloro, bromo, C_{1-4} alkyl, C_{1-4} alkoxy, CN or phenyl. Most preferably, R^4 is fluoro, chloro, C_{1-2} alkyl, C_{1-2} alkoxy or CN. Especially, R^4 is fluoro, chloro, methyl, methoxy or CN.

In another embodiment of the present invention, there is provided the compound of formula (Ia):



or a pharmaceutically acceptable salt thereof, wherein R^1 , R^2 , R^3 , R^4 , W, n, X, Y, Z and M are as defined in relation to formula (I);

D^1 is C and D^2 is N and the dotted line represents a double bond;

or D^1 is N and D^2 is CH and the dotted line represents a single bond;

ring C is a 5- or 6-membered ring optionally containing 1 or 2 heteroatoms selected from


N and S; and

ring D is a 5- or 6-membered ring optionally containing one or two N atoms.

Preferably, ring C is a 5- or 6-membered ring optionally containing 1 or 2 N atoms or one S atom. Examples of suitable C groups are phenyl, cyclohexenyl, cyclopentenyl, thienyl and imidazolyl. Preferably, ring D is a 5- or 6-membered ring optionally containing one N atom.


Examples of suitable D groups are phenyl and pyrrolyl.

In another embodiment of the present invention, there is provided the compound of formula (Iaa):




or a pharmaceutically acceptable salt thereof, wherein R^2 , R^3 , R^4 , W , n , X , M , D^1 , D^2 , ring C and ring D are as defined in relation to formula (Ia).

In another embodiment of the present invention, there is provided the compound of
 5 formula (Iab):




or a pharmaceutically acceptable salt thereof, wherein R^1 , R^2 , R^3 , R^4 , W , X , M and ring C are as defined in relation to formula (Ia).

In another embodiment of the present invention, there is provided the compound of
 10 formula (Iad):




or a pharmaceutically acceptable salt thereof, wherein R^1 , R^2 , R^3 , R^4 , W , X , M and ring C are as defined in relation to formula (Ia).

In another embodiment of the present invention, there is provided the compound of
 5 formula (Iae):



or a pharmaceutically acceptable salt thereof, wherein R^1 , R^2 , R^3 , R^4 , W , X , M and ring C are as defined in relation to formula (Ia).

In another embodiment of the present invention, there is provided the compound of
 10 formula (Ib):




or a pharmaceutically acceptable salt thereof, wherein R^1 , R^2 , R^3 , R^4 , W , X , Y , Z and M are as defined in relation to formula (I);

one of D^1 and D^2 is CH and the other of D^1 and D^2 is N; and

5 ring C is a 5- or 6-membered ring optionally containing 1 or 2 heteroatoms selected from N and S.

Preferably, ring C is a 5- or 6-membered ring optionally containing one N or S atom. An example of a suitable C group is phenyl.

10 In another embodiment of the present invention, there is provided the compound of formula (Iba):



or a pharmaceutically acceptable salt thereof, wherein R^1 , R^2 , R^3 , R^4 , W , X , M and ring C are as defined in relation to formula (Ib).

15 When any variable occurs more than one time in formula (I) or in any substituent, its definition on each occurrence is independent of its definition at every other occurrence.

As used herein, the term "alkyl" as a group or part of a group refers to any linear or branched chain alkyl group having a number of carbon atoms in the specified range. Thus, for

example, "C₁₋₆alkyl" refers to all of the hexyl alkyl and pentyl alkyl isomers as well as n-, iso-, sec- and t-butyl, n- and iso-propyl, ethyl and methyl. As another example, "C₁₋₄alkyl" refers to n-, iso-, sec- and t-butyl, n- and iso-propyl, ethyl and methyl.

5 The term "alkoxy" represents any linear or branched chain alkyl group having a number of carbon atoms in the specified range and attached through an oxygen bridge. Examples of suitable alkoxy groups include methoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy, s-butoxy, i-butoxy and t-butoxy.

10 The term "alkenyl" as a group or part of a group refers to any linear or branched chain alkyl group containing at least one double bond, which may occur at any point along the chain, and having a number of carbon atoms in the specified range. E- and Z-forms are both included, where applicable. Examples of suitable alkenyl groups include vinyl, allyl, butenyl and pentenyl.

15 The term "alkynyl" as a group or part of a group refers to any linear or branched chain alkyl group containing at least one triple bond, which may occur at any point along the chain, and having a number of carbon atoms in the specified range. Examples of suitable alkenyl groups include ethynyl, propynyl, butynyl and pentynyl.

The term "cycloalkyl" refers to any cyclic alkyl ring having a number of carbon atoms in the specified range. Examples of suitable cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.

20 The terms "alkylene", "alkenylene" and "alkynylene" as a group or part of a group refer to the groups "alkyl", "alkenyl" and "alkynyl" respectively, when they are divalent, i.e. attached at two atoms.

The term "halogen" or "halo" means fluorine, chlorine, bromine and iodine (alternatively referred to as fluoro, chloro, bromo and iodo, respectively).

25 The term "aryl" as a group or part of a group means a carbocyclic aromatic ring. Examples of suitable aryl groups include phenyl and naphthyl.

The term "Het" as a group or part of a group means a 5- to 7-membered saturated or unsaturated non-aromatic ring having 1 to 4 heteroatoms selected from N, O and S.

30 The term "heteroaryl" as a group or part of a group means a 5- to 10-membered heteroaromatic ring system containing 1 to 4 heteroatoms selected from N, O and S. Examples of such groups include pyrrolyl, furanyl, thienyl, pyridyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrazinyl, pyrimidinyl, pyridazinyl, triazolyl, oxadiazolyl, thiadiazolyl, triazinyl, tetrazolyl, indolyl, benzothienyl, benzimidazolyl, benzofuryl, quinolyl and isoquinolyl.

35 Unless expressly stated to the contrary, all ranges cited herein are inclusive. For example, a heteroaryl ring described as containing from "1 to 3 heteroatoms" means the ring can contain 1, 2, or 3 heteroatoms.

Where a compound or group is described as "optionally substituted" one or more substituents may be present. Furthermore, optional substituents may be attached to the compounds or groups which they substitute in a variety of ways, either directly or through a connecting group of which the following are examples: amine, amide, ester, ether, thioether,

sulfonamide, sulfamide, sulfoxide, urea, thiourea and urethane. As appropriate an optional substituent may itself be substituted by another substituent, the latter being connected directly to the former or through a connecting group such as those exemplified above.

Specific compounds within the scope of this invention include those named in the

5 Examples and Tables hereinbelow and their pharmaceutically acceptable salts.

For use in medicine, the salts of the compounds of formula (I) will be non-toxic pharmaceutically acceptable salts. Other salts may, however, be useful in the preparation of the compounds according to the invention or of their non-toxic pharmaceutically acceptable salts. Suitable pharmaceutically acceptable salts of the compounds of this invention include acid
10 addition salts which may, for example, be formed by mixing a solution of the compound according to the invention with a solution of a pharmaceutically acceptable acid such as hydrochloric acid, fumaric acid, p-toluenesulfonic acid, maleic acid, succinic acid, acetic acid, citric acid, tartaric acid, carbonic acid, phosphoric acid or sulfuric acid. Salts of amine groups may also comprise quaternary ammonium salts in which the amino nitrogen atom carries a suitable organic group
15 such as an alkyl, alkenyl, alkynyl or aralkyl moiety. Furthermore, where the compounds of the invention carry an acidic moiety, suitable pharmaceutically acceptable salts thereof may include metal salts such as alkali metal salts, e.g. sodium or potassium salts; and alkaline earth metal salts, e.g. calcium or magnesium salts.

The salts may be formed by conventional means, such as by reacting the free base form of
20 the product with one or more equivalents of the appropriate acid in a solvent or medium in which the salt is insoluble, or in a solvent such as water which is removed *in vacuo* or by freeze drying or by exchanging the anions of an existing salt for another anion on a suitable ion exchange resin.


The present invention includes within its scope prodrugs of the compounds of formula (I) above. In general, such prodrugs will be functional derivatives of the compounds of formula (I)
25 which are readily convertible *in vivo* into the required compound of formula (I). Conventional procedures for the selection and preparation of suitable prodrug derivatives are described, for example, in "Design of Prodrugs", ed. H. Bundgaard, Elsevier, 1985.

A prodrug may be a pharmacologically inactive derivative of a biologically active substance (the "parent drug" or "parent molecule") that requires transformation within the body in
30 order to release the active drug, and that has improved delivery properties over the parent drug molecule. The transformation *in vivo* may be, for example, as the result of some metabolic process, such as chemical or enzymatic hydrolysis of a carboxylic, phosphoric or sulfate ester, or reduction or oxidation of a susceptible functionality.

The present invention includes within its scope solvates of the compounds of formula (I)
35 and salts thereof, for example, hydrates.

The present invention also includes within its scope any enantiomers, diastereomers, geometric isomers and tautomers of the compounds of formula (I). It is to be understood that all such isomers and mixtures thereof are encompassed within the scope of the invention.

The preferred compounds of the present invention will have the stereochemistry as shown in formula (Ic):



The present invention further provides a compound of formula (I) or a pharmaceutically acceptable salt thereof for use in therapy.

The present invention also provides a compound of formula (I) or a pharmaceutically acceptable salt thereof for use in the treatment or prevention of infection by hepatitis C virus in a human or animal.

In another aspect, the invention provides the use of a compound of formula (I) as defined
10 above, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for
treatment or prevention of infection by hepatitis C virus in a human or animal.

A further aspect of the invention provides a pharmaceutical composition comprising a compound of formula (I) as defined above, or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable carrier. The composition may be in any suitable form, depending on the intended method of administration. It may for example be in the form of a tablet, capsule or liquid for oral administration, or of a solution or suspension for administration parenterally.

The pharmaceutical compositions optionally also include one or more other agents for the treatment of viral infections such as an antiviral agent, or an immunomodulatory agent such as α -, β - or γ -interferon.

In a further aspect, the invention provides a method of inhibiting hepatitis C virus protease and/or of treating or preventing an illness due to hepatitis C virus, the method involving administering to a human or animal (preferably mammalian) subject suffering from the condition a therapeutically or prophylactically effective amount of the pharmaceutical composition described above or of a compound of formula (I) as defined above, or a pharmaceutically acceptable salt thereof. “Effective amount” means an amount sufficient to cause a benefit to the subject or at least to cause a change in the subject’s condition.

30 The term "subject" (alternatively referred to herein as "patient") as used herein refers to an animal, preferably a mammal, most preferably a human, who has been the object of treatment, observation or experiment.

The dosage rate at which the compound is administered will depend on a variety of factors including the activity of the specific compound employed, the metabolic stability and length of action of that compound, the age of the patient, body weight, general health, sex, diet, mode and time of administration, rate of excretion, drug combination, the severity of the particular condition and the host undergoing therapy. Suitable dosage levels may be of the order of 0.02 to 5 or 10 g per day, with oral dosages two to five times higher. For instance, administration of from 10 to 50 mg of the compound per kg of body weight from one to three times per day may be in order. Appropriate values are selectable by routine testing. The compound may be administered alone or in combination with other treatments, either simultaneously or sequentially. For instance, it may be administered in combination with effective amounts of antiviral agents, immunomodulators, anti-infectives or vaccines known to those of ordinary skill in the art. It may be administered by any suitable route, including orally, intravenously, cutaneously and subcutaneously. It may be administered directly to a suitable site or in a manner in which it targets a particular site, such as a certain type of cell. Suitable targeting methods are already known.

An additional aspect of the invention provides a method of preparation of a pharmaceutical composition, involving admixing at least one compound of formula (I) as defined above, or a pharmaceutically acceptable salt thereof, with one or more pharmaceutically acceptable adjuvants, diluents or carriers and/or with one or more other therapeutically or prophylactically active agents.

As noted above, the present invention also relates to a method of inhibiting HCV NS3 protease, inhibiting HCV replication, or preventing or treating HCV infection with a compound of the present invention in combination with one or more therapeutic agents and a pharmaceutical composition comprising a compound of the present invention and one or more therapeutic agents selected from the group consisting of a HCV antiviral agent, an immunomodulator, and an anti-infective agent. Such therapeutic agents active against HCV include ribavirin, levovirin, viramidine, thymosin alpha-1, interferon- β , interferon- α , pegylated interferon- α (peginterferon- α), a combination of interferon- α and ribavirin, a combination of peginterferon- α and ribavirin, a combination of interferon- α and levovirin, and a combination of peginterferon- α and levovirin. Interferon- α includes recombinant interferon- α 2a (such as Roferon interferon available from Hoffmann-LaRoche, Nutley, NJ), pegylated interferon- α 2a (PegasysTM), interferon- α 2b (such as Intron-A interferon available from Schering Corp., Kenilworth, NJ), pegylated interferon- α 2b (PegIntronTM), a recombinant consensus interferon (such as interferon alphacon-1), and a purified interferon- α product. Amgen's recombinant consensus interferon has the brand name Infergen®. Levovirin is the L-enantiomer of ribavirin which has shown immunomodulatory activity similar to ribavirin. Viramidine represents an analog of ribavirin disclosed in WO 01/60379 (ICN Pharmaceuticals). In accordance with the method of the present invention, the individual components of the combination can be administered separately at different times during the course of therapy or concurrently in divided or single combination forms.

For the treatment of HCV infection, the compounds of the present invention may also be administered in combination with an agent that is an inhibitor of HCV NS3 serine protease. HCV NS3 protease inhibitors are disclosed in WO 98/22496, WO 98/46630, WO 99/07733, WO 99/07734, WO 99/38888, WO 99/50230, WO 99/64442, WO 00/09543, WO 00/59929, GB-
5 2337262, WO 02/48116, WO 02/48172, and U.S. Patent No. 6,323,180.

Ribavirin, levovirin, and viramidine may exert their anti-HCV effects by modulating intracellular pools of guanine nucleotides via inhibition of the intracellular enzyme inosine monophosphate dehydrogenase (IMPDH). Thus, inhibition of IMPDH represents another useful target for the discovery of inhibitors of HCV replication. Therefore, the compounds of the
10 present invention may also be administered in combination with an inhibitor of IMPDH, such as VX-497, disclosed in WO 97/41211 and WO 01/00622 (Vertex); another IMPDH inhibitor, such as that disclosed in WO 00/25780 (Bristol-Myers Squibb); or mycophenolate mofetil [see A.C. Allison and E.M. Eugui, Agents Action, 44 (Suppl.): 165 (1993)].

For the treatment of HCV infection, the compounds of the present invention may also be
15 administered in combination with the antiviral agent amantadine (1-aminoadamantane) [see J. Kirschbaum, Anal. Profiles Drug Subs. 12: 1-36 (1983)].

The compounds of the present invention may also be combined for the treatment of HCV infection with antiviral 2'-C-branched ribonucleosides disclosed in R. E. Harry-O'kuru, et al., J. Org. Chem., 62: 1754-1759 (1997); M. S. Wolfe, et al., Tetrahedron Lett., 36: 7611-7614
20 (1995); U.S. Patent No. 3,480,613; WO 01/90121; WO 01/92282; WO 02/32920; WO 04/002999; WO 04/003000; and WO 04/002422. Such 2'-C-branched ribonucleosides include 2'-C-methyl-cytidine, 2'-C-methyl-uridine, 2'-C-methyl-adenosine, 2'-C-methyl-guanosine, and 9-(2-C-methyl- β -D-ribofuranosyl)-2,6-diaminopurine, and the corresponding amino acid ester of the ribose C-2', C-3', and C-5' hydroxyls and the corresponding optionally substituted cyclic 1,3-
25 propanediol esters of the 5'-phosphate derivatives.


The compounds of the present invention may also be combined for the treatment of HCV infection with other nucleosides having anti-HCV properties, such as those disclosed in WO 02/51425 (Mitsubishi Pharma Corp.); WO 01/79246, WO 02/32920 and WO 02/48165 (Pharmasset, Ltd.); WO 01/68663 (ICN Pharmaceuticals); WO 99/43691; WO 02/18404
30 (Hoffmann-LaRoche); U.S. 2002/0019363; WO 02/100415; WO 03/026589; WO 03/026675; WO 03/093290; US 2003/0236216; US 2004/0006007; WO 04/011478; WO 04/013300; US 2004/0063658; and WO 04/028481.

For the treatment of HCV infection, the compounds of the present invention may also be administered in combination with an agent that is an inhibitor of HCV NS5B polymerase. Such
35 HCV NS5B polymerase inhibitors that may be used as combination therapy include those disclosed in WO 02/057287, US 6,777,395, WO 02/057425, US 2004/0067901, WO 03/068244, WO 2004/000858, WO 04/003138 and WO 2004/007512. Other such HCV polymerase inhibitors include valopicitabine (NM-283; Idenix) and 2'-F-2'-beta-methylcytidine (see also WO 2005/003147, assigned to Pharmasset, Ltd.).

The compounds of the present invention may also be combined for the treatment of HCV infection with non-nucleoside inhibitors of HCV polymerase such as those disclosed in WO 01/77091 (Tularik, Inc.); WO 01/47883 (Japan Tobacco, Inc.); WO 02/04425 (Boehringer Ingelheim); WO 02/06246, WO 03/062211, WO 2004/087714, WO 2004/110442, WO 2005/034941, WO 2005/023819, WO2006/029912, WO 2006/008556, WO 2006/027628 GB2430621, WO2006/046030, WO2006/046039, WO2006/119975, WO2007/028789 and WO2007/029029 (all Istituto di Ricerche di Biologia Molecolare P. Angeletti S.p.A.); WO 02/20497; WO 2005/016927 (in particular JTK003), and WO 2005/080399 (Japan Tobacco, Inc.); WO 2006/020082 (Bristol-Myers Squibb Company); and HCV-796 (Viropharma Inc.).


The present invention also provides a process for the preparation of compounds of formula (I).

According to a general process (a), compounds of formula (I) may be prepared by the coupling of the acid of formula (II) with the amine of formula (III):



where m , n , R^1 , R^a , R^b , R^3 , R^4 , M , W , X , Y , Z and ring A are as defined in relation to formula (I). The reaction is conveniently carried out in the presence of a coupling reagent, such as TBTU or HATU, and a base, such as diisopropylethylamine or triethylamine, in a solvent. Suitable solvents include DMF and dichloromethane.

The compound of formula (II) where M has 4 or more carbon atoms in the tether and one or more double bonds may be prepared by the internal ring closure of the diene of formula (IV):



where m, n, R³, R⁴, W, Y, Z and ring A are as defined in relation to formula (I), P¹ is C₁₋₆alkyl, such as methyl, and X' is a suitable precursor to or the same as X. The reaction is conveniently carried out in the presence of a metathesis catalyst, such as Zhan catalyst [dichloro(5-chloro-2-isopropoxybenzylidene)(1,3-dimethylimidazolidin-2-ylidene)ruthenium], preferably at raised
5 temperature, in a suitable solvent such as 1,2-dichloroethane. The resultant ring double bond may be hydrogenated to give a further compound of formula (II). The hydrogenation is preferably carried out in the presence of a suitable catalyst, such as palladium on carbon, in a suitable solvent, such as methanol/ethyl acetate mixture.

Compounds of formulae (II), (III) and (IV) are either well known in the art or may be prepared by conventional methodology well known to one of ordinary skill in the art using, for
10 instance, procedures described in the accompanying Schemes and Examples, or by alternative procedures which will be readily apparent.

Further details of suitable procedures will be found in the accompanying Schemes and Examples. For instance compounds of formula (I) can be converted into other compounds of
15 formula (I) using synthetic methodology well known in the art.

Thus, for instance, the compound of formula (I) where M is unsaturated may be converted into the compound of formula (I) where M is saturated by hydrogenation, preferably in the presence of a suitable catalyst, such as palladium on carbon, in a suitable solvent, such as
methanol/ethyl acetate mixture.

The compounds of the present inventions are useful in the inhibition of HCV protease (e.g., HCV NS3 protease) and the prevention or treatment of infection by HCV. For example, the compounds of this invention are useful in treating infection by HCV after suspected past exposure to HCV by such means as blood transfusion, exchange of body fluids, bites, accidental
20 needle stick, or exposure to patient blood during surgery.


The compounds of this invention are useful in the preparation and execution of screening assays for antiviral compounds. For example, the compounds of this invention are useful for isolating enzyme mutants, which are excellent screening tools for more powerful antiviral compounds. Furthermore, the compounds of this invention are useful in establishing or determining the binding site of other antivirals to HCV protease, e.g., by competitive inhibition.
25 Thus the compounds of this invention are commercial products to be sold for these purposes.

General Description of Synthesis:

The compounds of the present invention may be synthesised as outlined in the following general schemes.

Compounds above are generally accessible by formation of the central macrocyclic ring, followed by elaboration as shown in the following general scheme (P = protecting group, Q =
35 leaving group):


Scheme 1




The same general approach was used for the preparation of compounds in which ring C is
 5 attached to ring D rather than ring B.

General procedures for preparing intermediates for the Formula (A) are shown in **Schemes 2-3a:**


Scheme 2



Scheme 3




Scheme 3a



- 5 An alternative route to compounds of the invention (**Scheme 4**) was the construction of ring C from a suitable macrocyclic precursor; an example of this approach is the synthesis of the compounds exemplified below.

Scheme 4



During any of the above synthetic sequences, it may be necessary and/or desirable to protect sensitive or reactive groups on any of the molecules concerned. This may be achieved by means of conventional protecting groups such as those described in *Protective Groups in Organic Chemistry*, ed. J.F.W. McOmie, Plenum Press, 1973; and T.W. Greene & P.G.M. Wuts, *Protective Groups in Organic Synthesis*, John Wiley & Sons, 3rd ed., 1999. The protecting groups may be removed at a convenient subsequent stage using methods known from the art.

The HCV NS3 protease inhibitory activity of the present compounds may be tested using assays known in the art. One such assay is HCV NS3 protease time-resolved fluorescence (TRF) assay described as follows:

HCV NS3 protease time-resolved fluorescence (TRF) assay

The NS3 protease TRF assay was performed in a final volume of 100 μl in assay buffer containing 50 mM HEPES, pH 7.5, 150 mM NaCl, 15 % glycerol, 0.15 % Triton X-100, 10 mM DTT, and 0.1 % PEG 8000. The NS3 protease was pre-incubated with various concentrations of inhibitors for 10-30 minutes. The peptide substrate for the assay is Ac-C(Eu)-DDMEE-Abu-[COO]-

XSAK(QSY7)-NH₂, where Eu is an europium-labeled group, Abu is 1-aminobutanoic acid which connects an ester linkage with 2-hydroxy propanoic acid (X). Hydrolysis of the peptide by NS3 protease activity causes in separation of the fluorophore from the quencher, resulting in an increase in fluorescence. Activity of the protease was initiated by adding the TRF peptide substrate (final concentration 50-100 nM). The reaction was quenched after 1 hour at room temperature with 100 µl of 500 mM MES, pH 5.5. Product fluorescence was detected using either a Victor V2 or Fusion fluorimeter (Perkin Elmer Life and Analytical Sciences) with excitation at 340 nm and emission at 615 nm with 50-400 µs delay. Testing concentrations of different enzyme forms was selected with a signal to background ratio of 10-30. The inhibition constants were derived using a four-parameter fit.

The compounds of the present invention were active in the TRF assay with activities of <10µM.

Another suitable assay is the cellular Replicon or rheplisa assay described as follows:

Cell based HCV Replication Assay

Cell clones that stably maintain subgenomic HCV replicon were obtained by transfecting Huh-7 cells with an RNA replicon identical to I₃₇₇neo/NS3-3'/wt described by Lohmann *et al.* (1999) (EMBL-genbank No. AJ242652), followed by selection with neomycin sulfate (G418). Viral replication was monitored by measuring the expression of the NS3 protein by an ELISA assay performed directly on cells grown in 96 wells microtiter plates (Cell-ELISA) using the anti-NS3 monoclonal antibody 10E5/24 (as described in published International patent application WO 02/59321). Cells were seeded into 96 well plates at a density of 10⁴ cells per well in a final volume of 0.1 ml of DMEM/10% FCS. Two hours after plating, 50 µl of DMEM/10% FCS containing a 3x concentration of inhibitor were added, cells were incubated for 96 hours and then fixed for 10 minutes with ice-cold isopropanol. Each condition was tested in duplicate and average absorbance values were used for calculations. The cells were washed twice with PBS, blocked with 5% non-fat dry milk in PBS + 0.1% Triton X100 + 0.02% SDS (PBSTS) and then incubated o/n at 4 °C with the 10E5/24 mab diluted in Milk/PBSTS. After washing 5 times with PBSTS, the cells were incubated for 3 hours at room temperature with Fc specific anti-mouse IgG conjugated to alkaline phosphatase (Sigma), diluted in Milk/PBSTS. After washing again as above, the reaction was developed with p-nitrophenyl phosphate disodium substrate (Sigma) and the absorbance at 405/620 nm read at intervals. For calculations, we used data sets where samples incubated without inhibitors had absorbance values comprised between 1 and 1.5. The inhibitor concentration that reduced by 50% the expression of NS3 (IC₅₀) was calculated by fitting the data to the Hill equation,

$$\text{Fraction inhibition} = 1 - (A_i - b) / (A_0 - b) = [I]^n / ([I]^n + IC_{50})$$

where:

- A_i = absorbance value of HBI10 cells supplemented with the indicated inhibitor concentration.

- A_0 = absorbance value of HBI10 cells incubated without inhibitor.
- b = absorbance value of Huh-7 cells plated at the same density in the same microtiter plates and incubated without inhibitor.
- n = Hill coefficient.

5


The compounds of the present invention were active in the cell based HCV replication assay with activities $<50\mu\text{M}$, and especially $<5\mu\text{M}$.

Other examples of such assays are described in *e.g.*, published International patent application WO2005/046712. Compounds useful as HCV NS3 protease inhibitors would have a K_i less than $50\mu\text{M}$, more preferably less than $10\mu\text{M}$, most preferably less than $1\mu\text{M}$, especially less than 100 nM , and more especially less than 50 nM .

The following examples serve to illustrate the invention and its practice.

^1H NMR spectra were recorded on Bruker AM series spectrometers operating at (reported) frequencies between 300 and 600 MHz. Chemical shifts (δ) for signals corresponding to non-exchangeable protons (and exchangeable protons where visible) are recorded in parts per million (ppm) relative to tetramethylsilane and are measured using the residual solvent peak as reference. Signals are tabulated in the order: multiplicity (s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; b, broad, and combinations thereof); coupling constant(s) in Hertz (Hz); number of protons. Mass spectral (MS) data were obtained on a Perkin Elmer API 100, or Waters MicroMass ZQ, operating in negative (ES^-) or positive (ES^+) ionization mode and results are reported as the ratio of mass over charge (m/z). Preparative scale HPLC separations were carried out on a Waters Micromass System incorporating a 2525 pump module, a Micromass ZMD detector and a 2767 collection module, under Fraction Linx software or on a Shimadzu preparative system.

Zhan ruthenium metathesis catalyst RC-303 (Zhan catalyst 1B, RC-303, Zannan Pharma Ltd.)



30 List of Abbreviations

BOP	Benzotriazole-1-yl-oxy-tris-(dimethylamino)-phosphonium hexafluorophosphate
Brosyl chloride	4-Bromophenyl sulfonylchloride
CH_3CN	Acetonitrile
DABCO	1,4-Diazabicyclo[2.2.2]octane

	DBU	1,8-Diazabicyclo[5.4.0]undec-7-ene
	DCC	Dicyclohexylcarbodiimide
	DCE	Dichloroethane
	DCM	Dichloromethane
5	DMAP	4-Dimethylamino pyridine
	DIPEA	Diisopropylethylamine
	DMF	Dimethylformamide
	DMSO	Dimethyl Sulfoxide
	EDC	<i>N</i> -(3-Dimethylaminopropyl)- <i>N'</i> -ethylcarbodiimide
10	Et ₃ N	Triethylamine
	Et ₂ O	Diethyl ether
	EtOAc	Ethyl Acetate
	EtOH	Ethanol
	h	hour(s)
15	HATU	<i>O</i> -(7-Azabenzotriazol-1-yl)- <i>N,N,N',N'</i> -tetramethyluronium hexafluorophosphate
	HBr	Hydrobromic acid
	HCl	Hydrochloric acid
	HOAc	Acetic acid
	HOAt	1-Hydroxy-7-azabenzotriazole
20	HOBT	1-hydroxybenzotriazole
	LiOH	Lithium hydroxide
	MeOH	Methanol
	min	minute(s)
	MgSO ₄	Magnesium sulfate
25	Na ₂ SO ₄	Sodium sulfate
	NaHCO ₃	Sodium bicarbonate
	NaOH	Sodium hydroxide
	NH ₄ Cl	Ammonium chloride
	NH ₄ OH	Ammonium hydroxide
30	NMP	N-methyl-pyrrolidinone
	Nle	Norleucine
	Pd/C	Palladium on carbon
	PhMe	Toluene
	PPh ₃	Triphenylphosphine
35	RT	Room temperature
	TBAF	Tetrabutylammonium fluoride
	TBTU	<i>O</i> -Benzotriazol-1-yl- <i>N,N,N',N'</i> -tetramethyluronium tetrafluoroborate
	TEA	Triethylamine
	THF	Tetrahydrofuran

Synthesis of Intermediates:**Preparation of Intermediates A**

5

Intermediate	Name	Lit. Reference
A1	(1 <i>R</i> ,2 <i>S</i>)-1-Amino- <i>N</i> -(cyclopropylsulfonyl)-2-vinylcyclopropanecarboxamide hydrochloride	Wang et al, US 6,995,174
A2	Ethyl (1 <i>R</i> ,2 <i>S</i>)-1-amino-2-vinylcyclopropanecarboxylate hydrochloride	Llinas-Brunet et al, US 6,323,180

Intermediate A3: (1*R*,2*R*)-1-Amino-*N*-(cyclopropylsulfonyl)-2-ethylcyclopropanecarboxamide hydrochloride

Step 1: *tert*-Butyl ((1*R*,2*R*)-1-{[(cyclopropylsulfonyl)amino]carbonyl}-2-

10 ethylcyclopropyl)carbamate

A hydrogenation vessel was charged with a methanol (1000 mL) slurry of *tert*-butyl ((1*R*,2*S*)-1-
 {[(cyclopropylsulfonyl)amino]carbonyl}-2-vinylcyclopropyl)carbamate (164 g, 0.50 mol) and 5%
 Ru/C (dry, 7.5 wt%, 12.4 g) and stirred. The vessel was placed under nitrogen (20 psig) and
 vented to atmospheric pressure three times to remove residual oxygen. The vessel was then
 15 placed under hydrogen (50 psig). After 20 h, the vessel was vented to atmospheric pressure. The
 reaction slurry was then transferred out of the reaction and filtered through solka flock (34 grams,
 wetted w/ 100 mL MeOH) to yield a clear, light brown solution. The solka flock was rinsed with
 MeOH (200 mL x 2). The combined methanol solutions were concentrated under reduced
 pressure to yield crude product as a white solid (153 g). The crude product was slurried in
 20 EtOAc (800 mL), warmed to 40 °C and aged 30 min. The solution was then seeded, aged 30
 min, and heptane (500 mL) was added via addition funnel over 30 min. The partially crystallized
 solid was cooled to RT and aged overnight after which additional heptane (500 mL) was added.
 After 1 h, additional heptane (250 mL) was added via addition funnel, and the white slurry aged
 for 1 h. The solution was filtered and the solid was rinsed with heptane/EtOAc (500 mL, 4:1) and
 25 dried under reduced pressure to give *tert*-butyl ((1*R*,2*R*)-1-
 {[(cyclopropylsulfonyl)amino]carbonyl}-2-ethylcyclopropyl)carbamate (125.9 g).

Step 2: (1*R*,2*R*)-1-Amino-*N*-(cyclopropylsulfonyl)-2-ethylcyclopropanecarboxamide
 hydrochloride (Intermediate A3)

30 A solution of the product from Step 1 above (92 g, 0.28 mol) in DCM (1200 mL) was cooled to
 0 °C and HCl bubbled through the solution for 10 min, the cooling bath removed and the reaction
 mixture stirred for 2 h. Nitrogen was bubbled through the reaction mixture for 5 min and the
 volatiles evaporated. The residue was azeotroped with DCM (x3) to give an off white powder
 (75 g). LRMS (M+H)⁺ Calcd. = 233; found 233

Preparation of Intermediates B

Intermediate B1: *N*-[(pent-4-en-1-yloxy)carbonyl]-L-norleucine:

5 To a solution of 1-penten-4-ol (0.95 g, 11.0 mmol) in DMF (15 mL) at 0 °C was added carbonyldiimidazole (1.79 g, 11.0 mmol). The reaction mixture was warmed to RT and stirred for 30 min. L-norleucine methyl ester hydrochloride (2.0 g, 11.0 mmol) was then added, the reaction mixture was heated to 50 °C and stirred for 15 min. Upon cooling, the reaction mixture was diluted with Et₂O and washed twice with water. The organic layer was dried over sodium
10 sulfate, filtered and concentrated. The crude product was purified by silica gel chromatography (gradient elution 10 to 90% EtOAc in hexanes) to afford 2.1 g (74%) methyl *N*-[(pent-4-en-1-yloxy)carbonyl]-L-norleucinate as a clear oil.

To a stirred solution of methyl *N*-[(pent-4-en-1-yloxy)carbonyl]-L-norleucinate (8.50g, 33.03 mmol) in THF (20 mL) was added 1N NaOH (20 mL). This reaction solution was stirred at RT
15 for 3 h, then acidified to pH 3 with 1N HCl and extracted with (3 x 250 mL) EtOAc. The combined EtOAc layer was washed with 50 mL water, 50 mL brine, dried over sodium sulfate, filtered and concentrated to give 7.09 g (88%) of the title product as clear oil. LRMS (ESI) *m/z* 244 [(M+H)⁺; calcd for C₁₂H₂₂NO₄: 244].

20 **Intermediate B2:** (2S)-3,3-dimethyl-2-{[(pent-4-en-1-yloxy)carbonyl]amino}butanoic acid
Diisopropylethyl amine (9.85 g, 76.2 mmol) was added dropwise to a 0 °C solution of 4-penten-1-ol (7.22 g, 83.9 mmol) and triphosgene (11.3 g, 38.1 mmol) in 160 mL dioxane. The resulting white suspension was stirred for 5 min at 0 °C, then allowed to warm to 25 °C over 1 h. The suspension was cooled to 0 °C with an ice bath and 1 N NaOH (76.2 mL) and L-*tert*-butylglycine
25 (10.0 g, 76.2 mmol) were added. The reaction mixture was warmed to 25 °C and stirred for 18 h. The dioxane was removed *in vacuo* and the reaction mixture was basified to pH 12 with 1 N NaOH. The aqueous layer was extracted with DCM (3x 150 mL), then acidified to pH~1 with 6 N HCl. The aqueous layer was extracted with DCM (3 x 150 mL). The combined organic layers were dried over MgSO₄ and concentrated to give the compound as a tan oil (13.7 g, 73.9%
30 yield). LRMS (ESI) *m/z* 244 [(M+H)⁺; calcd for C₁₂H₂₂NO₄: 244].

The following carbamate intermediates (B3-B24) were prepared using the chemistry described for the preparation of (2S)-3,3-dimethyl-2-{[(pent-4-en-1-yloxy)carbonyl]amino}butanoic acid (B2), by utilizing the appropriate amino acid and alcohol.
35 Compounds in Table 1 having a basic group or acidic group are depicted and named as the free base or acid. Depending on the reaction and purification conditions, various compounds in Table 1 having a basic group were isolated in either the free base form, or as a salt (such as HCl salt), or in both free base and salt forms. Various compounds in the table having an acid group were isolated in either the acid form, or as a salt (such as Na salt), or in both acid and salt forms.

Int	Amino Acid	Alcohol	Name	LRMS (M+H) ⁺
B3	L-Norleucine	3-Buten-1-ol	<i>N</i> -[(but-3-en-1-yloxy)carbonyl]-L-norleucine	230.3
B4	L-Norleucine	5-Hexen-1-ol	<i>N</i> -[(hex-5-en-1-yloxy)carbonyl]-L-norleucine	258.3
B5	L-Norleucine	6-Hepten-1-ol	<i>N</i> -[(hept-6-en-1-yloxy)carbonyl]-L-norleucine	272.3
B6	L-Norleucine	7-Octen-1-ol	<i>N</i> -[(oct-7-en-1-yloxy)carbonyl]-L-norleucine	286.4
B7	L-Valine	4-Penten-1-ol	<i>N</i> -[(Pent-4-en-1-yloxy)carbonyl]-L-valine	230.3
B8	L-Valine	4-Propen-1-ol	<i>N</i> -[(allyloxy)carbonyl]-L-valine	202.2
B9	L-Valine	4-Buten-1-ol	<i>N</i> -[(but-3-en-1-yloxy)carbonyl]-L-valine	216.3
B10	L- <i>tert</i> -leucine	5-Hexen-1-ol	<i>N</i> -[(Hex-5-en-1-yloxy)carbonyl]-3-methyl-L-valine	258.3
B11	L- <i>tert</i> -leucine	6-Hepten-1-ol	<i>N</i> -[(Hept-6-en-1-yloxy)carbonyl]-3-methyl-L-valine	272.3
B12	L- <i>tert</i> -leucine	3-Buten-1-ol	<i>N</i> -[(But-3-en-1-yloxy)carbonyl]-3-methyl-L-valine	230.3
B13	L- <i>tert</i> -leucine	2,2-Dimethyl hex-5-en-1-ol Ref: <i>J. Org. Chem.</i> (1991), 56, 1623	<i>N</i> -{[(2,2-Dimethylhex-5-en-1-yl)oxy]carbonyl}-3-methyl-L-valine	286.3
B14	L- <i>tert</i> -leucine	Allyl alcohol	<i>N</i> -[(allyloxy)carbonyl]-3-methyl-L-valine	215.2
B15	L- <i>tert</i> -leucine	7-Octen-1-ol	3-Methyl- <i>N</i> -[(oct-7-en-1-yloxy)carbonyl]-L-valine	286.3
B16	L-Cyclohexyl-glycine	6-Hepten-1-ol	(2 <i>S</i>)-Cyclohexyl {[hept-6-en-1-yloxy]carbonyl}amino}acetic acid	298.3
B17	L-Cyclohexyl-glycine	5-Hexen-1-ol	(2 <i>S</i>)-Cyclohexyl {[hex-5-en-1-yloxy]carbonyl}amino}acetic acid	284.4
B18	L- <i>tert</i> -leucine	6-Heptyn-1-ol	<i>N</i> -[(hept-6-yn-1-yloxy)carbonyl]-3-methyl-L-valine	270.2
B19	L-Cyclohexyl-glycine	2,2-dimethylhept-6-en-1-ol. Ref: WO2005/030796	(2 <i>S</i>)-cyclohexyl {[2,2-dimethylhept-6-en-1-yl]oxy]carbonyl}amino}acetic acid	326.5
B20	L-Cyclohexyl-glycine	2,2-Dimethylpent-4-en-1-ol Ref: <i>Tetrahedron</i>	(2 <i>S</i>)-cyclohexyl {[2,2-dimethylpent-4-en-1-yl]oxy]carbonyl}amino}acetic acid	298.3

		(1987), 43, 5637		
B21	L-Cyclopentyl-glycine	2,2-Dimethyl pent-4-en-1-ol Ref: <i>Tetrahedron</i> (1987), 43, 5637	(2 <i>S</i>)-cyclopentyl({[(2,2-dimethylpent-4-en-1-yl)oxy]carbonyl}amino)acetic acid	284.3
B22	L-Cyclohexyl-glycine	2-allylcyclopentanol Ref: <i>JACS</i> (1982), 104, 2444	(2 <i>S</i>)-({[(2-allylcyclopentyl)oxy]carbonyl}amino)(cyclohexyl)acetic acid	310.3
B23	L- <i>tert</i> -leucine	2,2-Dimethyl pent-4-en-1-ol Ref: <i>Tetrahedron</i> (1987), 43, 5637.	<i>N</i> -{[(2,2-dimethylpent-4-en-1-yl)oxy]carbonyl}-3-methyl-L-valine	272.3
B24	L-Norleucine	2,2-Dimethyl pent-4-en-1-ol Ref: <i>Tetrahedron</i> . (1987), 43, 5637.	<i>N</i> -{[(2,2-dimethylpent-4-en-1-yl)oxy]carbonyl}-L-norleucine	272
B25	L-Cyclopentyl glycine	2,2-dimethylhept-6-en-1-ol Ref: <i>J. Org. Chem.</i> (1980), 43, 2685.	(2 <i>S</i>)-cyclopentyl({[(2,2-dimethylhept-6-en-1-yl)oxy]carbonyl}amino)acetic acid	312

Intermediate B26: 3-methyl-*N*-{[methyl(pent-4-en-1-yl)amino]carbonyl}-L-valine

Step 1: Methyl 3-methyl-*N*-{[methyl(pent-4-en-1-yl)amino]carbonyl}-L-valinate

To a solution of *N*-methylpent-4-en-1-amine (ref: *Org. Biomol. Chem.*; EN; 2; 20; 2004; 3006 – 3017) (2.0 g, 21.2 mmol) in THF (20 mL) was added methyl 3-methyl-*N*-(oxomethylene)-L-valinate (Ref: EP 0 486 948 A2) (3.5 g, 20.2 mmol). After 2 h, the solvent was removed *in vacuo* and the crude material was purified on silica (40% EtOAc/hexanes) to yield the title compound. LRMS (M+H)⁺ 271.3

Step 2: *N*-{[(1,1-Dimethylpent-4-en-1-yl)amino]carbonyl}-L-valine

To a solution of the product from Step 1, methyl 3-methyl-*N*-{[methyl(pent-4-en-1-yl)amino]carbonyl}-L-valinate, (3.0 g, 11.2 mmol) in THF (40 mL) was added 1M lithium hydroxide (56.0 mL, 1 M solution 56.0 mmol). The reaction mixture was stirred at 50 °C under nitrogen for 1 h, cooled to r.t. and THF removed *in vacuo*. Aqueous KHSO₄ was then added and the mixture extracted with DCM (3x). The combined organic extracts were dried over anhydrous Na₂SO₄ and the solvent was removed *in vacuo* to give the title compound as a colorless oil (2.95 g). LRMS (M+H)⁺ = 257.3.

Int	Amino Acid	Amine	Name	LRMS (M+H) ⁺
B26	L- <i>tert</i> -leucine	<i>N</i> -methylpent-4-en-1-amine Ref: <i>Org. Biomol. Chem.</i> 2;	3-methyl- <i>N</i> -{[methyl(pent-4-en-1-yl)amino]carbonyl}-L-valine	257.3

		20; 2004; 3006 – 3017		
B27	L-Cyclohexyl-glycine	<i>N</i> ,2,2-trimethylpent-4-en-1-amine	(2 <i>S</i>)-cyclohexyl({[(2,2-dimethylpent-4-en-1-yl)(methyl)amino]carbonyl}amino)acetic acid	311.4
B28	L-Cyclopentyl-glycine	<i>N</i> -methylhept-6-en-1-amine	(2 <i>S</i>)-cyclopentyl({[hept-6-en-1-yl(methyl)amino]carbonyl}amino)acetic acid	297.1

Preparation of Intermediates C

Intermediate C1: 8-bromo-9-methoxy-6-oxo-5,6-dihydrophenanthridine-3-carbonitrile

5 Step 1: 1-bromo-4-iodo-2-methoxybenzene

To a suspension of 4-bromo-3-methoxyaniline (25 g, 124 mmol) in concentrated HCl (1.7 L) cooled to 0 °C was added sodium nitrite (11.1 g, 161 mmol) in water (250 mL) slowly over 30 min keeping the temperature below 8 °C. After stirring for 2h, to the resulting orange solution was added KI (61.6 g, 371 mmol) in water (250 mL) slowly over 30 min keeping the temperature
10 below 8 °C. The mixture was then warmed to r.t. and stirred for a further 1.5 h. It was then filtered through a sintered glass wool funnel. The resulting solid was dissolved in EtOAc (1.2 L) and washed with water, 0.5 N NaOH, aq. sodium bisulfite, and brine. The organic layer was then dried over Na₂SO₄, filtered through a pad of silica, and then solvent was removed *in vacuo*. The crude material was purified on silica (100% hexanes) to yield the title product.

15 Step 2: 2-amino-4'-bromo-3'-methoxybiphenyl-4-carbonitrile
To a mixture of the product from Step 1, 1-bromo-4-iodo-2-methoxybenzene (750 mg, 2.4 mmol), CsF (1.09 g, 7.2 mmol), (2-amino-4-cyanophenyl)boronic acid hydrochloride (390 mg, 2.4 mmol), and Pd(PPh₃)₄ (277 mg, 0.24 mmol) was added DME (15 mL) under N₂. It was then
20 heated to 100 °C. After 36 h, to the thick red suspension was added EtOAc and water. The organic layer was washed with brine, dried over Na₂SO₄, and the solvent was removed *in vacuo*. The residue was purified on silica (gradient elution, 3-50% EtOAc/hex) to yield the title compound as a red oil. LRMS (M+H)⁺ = 303.1.

25 Step 3: 8-bromo-9-methoxy-6-oxo-5,6-dihydrophenanthridine-3-carbonitrile

To the product from Step 2, 2-amino-4'-bromo-3'-methoxybiphenyl-4-carbonitrile (363 mg, 1.2 mmol) was added phosgene (20% solution in PhMe, 5.9 g, 11.97 mmol) and the mixture was heated to reflux for 2h. The solvent was then removed *in vacuo* to give crude 4'-bromo-2-isocyanato-3'-methoxybiphenyl-4-carbonitrile (394 mg, 1.2 mmol) which was then taken up in
30 chlorobenzene (4 mL). To this mixture was then added AlCl₃ (319 mg, 2.4 mmol) at r.t. 1 N HCl (30 mL) was then added which caused a grey precipitate to form. This was isolated by

filtration and washed with DCM and MeOH to give the title compound. LRMS (M+H)⁺ = 329.0.

Intermediate C2: 8-bromo-3,9-dimethoxyphenanthridin-6(5H)-one

5 Step 1: 4'-bromo-3',4-dimethoxy-2-nitrobiphenyl

To a solution of 1-iodo-4-methoxy-2-nitrobenzene (5 g, 17.9 mmol) in THF (50 mL) cooled to -60 °C was added phenylmagnesium bromide (10.4 mL, 25 wt%, 19.7 mmol) which gave a dark red solution. Trimethylborate (2.4 mL, 21.5 mmol) was then added dropwise. After 30 min, the reaction was quenched with 1 N HCl (40 mL) and extracted with ether. The organic layer was then dried over Na₂SO₄ and the solvent was removed *in vacuo* to give a dark brown oil which was triturated with DCM to yield (4-methoxy-2-nitrophenyl)boronic acid as grey solid. A portion of this material (1.57 g, 8 mmol) was then taken up in DME (1 mL) and 1-bromo-4-iodo-2-methoxybenzene (C1, step 1) (2.5 g, 8 mmol), CsF (2.73 g, 18 mmol), and tetrakis(triphenylphosphine) palladium (0.92 g, 0.8 mmol) under nitrogen. The mixture was then heated to 100 °C for 18 h. The mixture was then extracted with water and EtOAc. The organic layer was then dried over Na₂SO₄ and the solvent was removed *in vacuo*. The crude material was then purified on silica (gradient elution, 3-50% EtOAc/hexanes) to yield the title compound as a yellow solid.

20 Step 2: 4'-bromo-3',4-dimethoxybiphenyl-2-amine

To a solution of the product from Step 1, 4'-bromo-3',4-dimethoxy-2-nitrobiphenyl (1.5 g, 4.4 mmol) in THF (10 mL) was added HCl (12M, 9.24 mL, 111 mmol) and iron powder (4.48 g, 80.2 mmol). After 3 days at r.t., the solution was basified with saturated NaOH and extracted with EtOAc. The organic layer was then dried over Na₂SO₄ and the solvent was removed *in vacuo*. The crude material was then purified on silica (gradient elution, 5-45% EtOAc/hexanes) to yield the title compound as an orange foam. LRMS (M+H)⁺ = 308.2.

Step 3: 8-bromo-3,9-dimethoxyphenanthridin-6(5H)-one

The title compound was prepared according to Step 3 of intermediate C1. LRMS (M+H)⁺ = 334.1.

The following intermediates (C3-C6) were prepared using the chemistry described for the preparation of 8-bromo-9-methoxy-6-oxo-5,6-dihydrophenanthridine-3-carbonitrile (C1) or 8-bromo-3,9-dimethoxyphenanthridin-6(5H)-one (C2), by utilizing the appropriate aminoboronic acid or ester in step 2 (C1) or nitroboronic acid in step 1 (C2).

Compounds in Table 1 having a basic group or acidic group are depicted and named as the free base or acid. Depending on the reaction and purification conditions, various compounds in Table 1 having a basic group were isolated in either the free base form, or as a salt (such as HCl salt), or

in both free base and salt forms. Various compounds in the table having an acid group were isolated in either the acid form, or as a salt (such as Na salt), or in both acid and salt forms.

Int.	Proce-dure	Name	LRMS (M+H) ⁺
C3	C1	8-bromo-9-methoxyphenanthridin-6(5H)-one	304.2
C4	C1	8-bromo-9-methoxy-3-methylphenanthridin-6(5H)-one	318.2
C5	C2	8-bromo-3-fluoro-9-methoxyphenanthridin-6(5H)-one	322.1
C6	C1	8-bromo-2-chloro-9-methoxyphenanthridin-6(5H)-one	338.2

5 **Intermediate C7: 6-bromo-2-ethoxybenzo[*h*]quinolin-4-ol**

Step 1: ethyl 3-ethoxy-3-iminopropanoate hydrochloride

To a solution of ethyl cyanoacetate (5 g, 44.2 mmol) in Et₂O (4.5 mL) was added EtOH (2.84 mL, 48.6 mmol). HCl (g) was then bubbled into the solution for 10 min at 0 °C. The mixture was then warmed to r.t. and stirred overnight. The solvent was then removed *in vacuo* to yield the title compound as a white powder. LRMS (M+H)⁺ = 160.3.

Step 2: ethyl (3*E*)-3-[(4-bromo-1-naphthyl)imino]-3-ethoxypropanoate

To a solution of the product from Step 1, ethyl 3-ethoxy-3-iminopropanoate hydrochloride (5.27 g, 26.9 mmol) in EtOH (60 mL) was added 4-bromonaphthalen-1-amine (3.42 g, 15.4 mmol) under N₂ and the mixture was stirred at r.t. after sonicating for 5 min. After overnight, the resulting solid was removed by filtration and the solvent was removed *in vacuo*. The crude product was purified on silica (gradient elution, 0-30% EtOAc/hexanes) to yield the title compound as an oil. LRMS (M+H)⁺ = 364.1.

20 Step 3: 6-bromo-2-ethoxybenzo[*h*]quinolin-4-ol

To refluxing Dowtherm A (50 mL) was added the product from Step 2, ethyl (3*E*)-3-[(4-bromo-1-naphthyl)imino]-3-ethoxypropanoate (5.61 g, 15.4 mmol) in Dowtherm A (5 mL). The mixture was then heated at this temperature for 5 min, and then cooled to r.t. The mixture was then diluted with hexanes and the resulting solid was removed by filtration. The solid was washed with additional hexanes to yield the title compound as a brown solid. LRMS (M+H)⁺ = 318.1.

Intermediate C8: 8-bromo-6-chloro-9-methoxy-1,2,3,4-tetrahydrophenanthridine

Step 1: ethyl 2-[[trifluoromethyl)sulfonyl]oxy]cyclohex-1-ene-1-carboxylate

To a solution of ethyl cyclohexanone-2-carboxylate (5.02 g, 29.5 mmol) in DCM (100 mL) cooled to -78 °C was added DIPEA (25.4 mL, 146 mmol) and then triflic anhydride (5.98 mL,

35.4 mmol) dropwise. The mixture was then warmed to r.t. and stirred overnight. The reaction was then quenched with aqueous citric acid and extracted with additional water. The organic layer was dried over Na₂SO₄ and the solvent was removed *in vacuo*. The crude product was purified on silica (100% DCM) to give the title product as an oil.

5

Step 2: ethyl 2-(4-bromo-3-methoxyphenyl)cyclohex-1-ene-1-carboxylate

To a solution of the product from Step 1, ethyl 2-[(trifluoromethyl)sulfonyl]oxy}cyclohex-1-ene-1-carboxylate (6.65 g, 22.0 mmol) in dioxane (125 mL) was added potassium carbonate (4.56 g, 33.0 mmol), PPh₃ (0.346 g, 1.32 mmol), bis(pinacolato)diboron (6.15 g, 24.20 mmol), and PdCl₂(PPh₃)₂ (0.463 g, 0.66 mmol). The mixture was then heated to 80 °C overnight. This solution was then cooled to r.t. and added to a mixture of 1-bromo-4-iodo-2-methoxybenzene (6.86 g, 21.92 mmol), PdCl₂(dppf) (0.481 g, 0.657 mmol), potassium carbonate (9.09 g, 65.7 mmol). This mixture was then heated to 80 °C overnight. The mixture was then cooled to r.t., diluted with EtOAc (300 mL) and washed with brine and aqueous KHSO₄. The organic layer was then dried over Na₂SO₄ and the solvent was removed *in vacuo*. The crude material was then purified on silica (100% DCM) to give impure product which was repurified on silica (gradient elution, 5-20% EtOAc/hexanes) to give the title compound.

Step 3: 8-bromo-9-methoxy-1,3,4,5-tetrahydrophenanthridin-6(2H)-one

To a solution of the product from Step 2, ethyl 2-(4-bromo-3-methoxyphenyl)cyclohex-1-ene-1-carboxylate (2.0 g, 5.9 mmol) in THF (120 mL), EtOH (50 mL), and water (12 mL) was added LiOH (0.565 g, 23.6 mmol) and the reaction was stirred at 70 °C for 24 h. After cooling to r.t., the EtOH and THF were removed *in vacuo* and the aqueous layer was washed with Et₂O. The pH was then adjusted to 1.4 with concentrated HCl and extracted with DCM two times. The organic layer was then dried over Na₂SO₄ and the solvent was removed *in vacuo* to yield 2-(4-bromo-3-methoxyphenyl)cyclohex-1-ene-1-carboxylic acid, which was dissolved in PhMe (9.6 mL) and treated with TEA (0.94 mL, 6.75 mmol) and diphenylphosphoryl azide (1.04 mL, 4.82 mmol). After 1 h at r.t., the mixture was filtered through a pad of silica washing with PhMe. Diphenylmethane (10 mL) was then added and the PhMe was removed *in vacuo*. The mixture was then heated to 250 °C for 2 h, cooled to r.t., the solids were removed by filtration, and washed with hexanes to give the title product as a tan solid. LRMS (M+H)⁺ = 307.9.

Step 4: 8-bromo-6-chloro-9-methoxy-1,2,3,4-tetrahydrophenanthridine

To the product from Step 3, 8-bromo-9-methoxy-1,3,4,5-tetrahydrophenanthridin-6(2H)-one (880 mg, 2.86 mmol) was added POCl₃ (6 mL, 64.4 mmol) and the mixture was heated to 80 °C for 3 h. The excess POCl₃ was then removed *in vacuo*, the residue was dissolved in DCM and the pH was adjusted to 5 with 1N NaOH. The organic layer was then dried over Na₂SO₄ and the solvent was removed *in vacuo*. The resulting solid was triturated with ether to yield the title compound as a light yellow solid. LRMS (M+H)⁺ = 325.8.

Intermediate C9: 7-bromo-5-chloro-8-methoxy-2,3-dihydro-1*H*-cyclopenta[*c*]isoquinoline

The title compound was prepared according to the procedure for intermediate C8 starting from methyl 2-oxocyclopentanecarboxylate in place of ethyl cyclohexanone-2-carboxylate in Step 1.

5 LRMS (M+H)⁺ = 311.8.

Intermediate C10: 3-allyl-1-methyl-3*H*-pyrrolo[2,3-*c*]quinolin-4-ol

Ref. Alazard et. al. Bioorg Med Chem Lett. 1991, 1, 725-728

Step 1: 1-Nitro-2-[2-nitroprop-1-en-1-yl]benzene

10 A solution of 2-nitrobenzaldehyde (5.0 g, 33.1 mmol) and ammonium acetate (2.55 g, 33.1 mmol) in AcOH (20 mL) was treated dropwise at 20 °C with nitroethane (2.84 mL, 39.7 mmol). The resulting solution was heated under reflux for 2 h, then cooled and diluted with EtOAc. The organic layer was washed with saturated aqueous NaHCO₃ solution and brine, then dried over Na₂SO₄. Filtration and removal of the volatiles gave a residue that was purified on silica gel
15 (gradient elution, 0-40% EtOAc/hexanes) to give the title compound as an oil. (2.3 g, 33%).
LCMS (ES+) m/z 209 (M+H)⁺

Step 2: Ethyl 4-methyl-3-(2-nitrophenyl)-1*H*-pyrrole-2-carboxylate

20 A solution of 1-nitro-2-[2-nitroprop-1-en-1-yl]benzene (4.1 g, 19.7 mmol) in a mixture of THF (131 mL) and *tert*-BuOH (66 mL) was treated with DBU (4.45 mL, 29.5 mmol) and ethyl isocyanoacetate (2.67 g, 2.58 mL) added. The resulting solution was stirred for 1 h then heated to 70 °C for 4 h. The mixture was cooled and concentrated *in vacuo* to give a residue was taken up in EtOAc and aqueous HCl (1 N). The organic layer was separated and washed with brine then dried over Na₂SO₄. Filtration and solvent removal afforded a residue that was purified on
25 silica gel (gradient elution, 0-40% EtOAc/hexanes) to afford the title compound (3.2 g, 59%) as solid. LCMS (ES+) m/z 275 (M+H)⁺

Step 3: 1-methyl-3*H*-pyrrolo[2,3-*c*]quinolin-4-ol

30 A solution of ethyl 4-methyl-3-(2-nitrophenyl)-1*H*-pyrrole-2-carboxylate (3.2 g, 11.67 mmol) in AcOH (117 mL) was treated at 20 °C with iron dust (6.52 g, 117 mmol). The reaction mixture was heated at 100 °C for 3 h. The white precipitate was removed by filtration and the filtrates were concentrated to give a residue that was purified on silica gel (gradient elution, 50-100% MeOH/Acetone) to afford the title compound (2.0 g, 86%) as a solid. LCMS (ES+) m/z 199 (M+H)⁺.

35

Step 4: 3-allyl-1-methyl-3*H*-pyrrolo[2,3-*c*]quinolin-4-ol

A solution of 1-methyl-3*H*-pyrrolo[2,3-*c*]quinolin-4-ol (1.2 g, 6.05 mmol) in a mixture of THF (30 mL) and NMP (60 mL) was treated with Cs₂CO₃ (2.95 g, 9.08 mmol). Allyl bromide (0.524 mL, 6.06 mmol) was added dropwise, and the resulting mixture was stirred at 40 °C for 12 h.

The mixture was cooled and quenched with aqueous HCl (1 N) and EtOAc. The organic layer was separated, washed with aqueous HCl (1 N), brine, and dried over Na₂SO₄. Filtration and removal of the volatiles gave a residue that was triturated with Et₂O to give the title compound (0.78 g, 54 %) as a solid. LCMS (ES⁺) *m/z* 239 (M+H)⁺.

5

Intermediate C11: 3-allyl-7-methoxy-1-methyl-3H-pyrrolo[2,3-*c*]quinolin-4-ol

Prepared from 2-nitro-4-methoxybenzaldehyde according to the procedures described for intermediate C10. LCMS (ES⁺) *m/z* 269 (M+H)⁺.

10 **Intermediate C12:** 7-bromo-8-methoxythieno[2,3-*c*]isoquinolin-5-ol

Step 1: 3-(4-bromo-3-methoxyphenyl)thiophene-2-carboxylic acid

A solution of 3-(dihydroxyboryl)thiophene-2-carboxylic acid (1.89 g, 10.85 mmol) and 1-bromo-4-iodo-2-methoxybenzene (3.09 g, 9.86 mmol) in a 3:1 mixture of MeCN:H₂O (100 mL) was treated with K₂CO₃ (4.09 g, 29.6). Pd(OAc)₂ (66.4 mg, 0.30 mmol) and biphenyl-2-

15 yl(dicyclohexyl)phosphine (207 mg, 0.59 mmol) were added and the mixture was stirred at 90 °C for 3 h. The mixture was cooled and concentrated, and the residue was added at 0 °C to a mixture of 10% aqueous NaOH (100 mL) and DCM. The mixture was acidified to pH = 1 by addition of aqueous HCl (6 N) and the solid precipitate was collected by filtration, washed with cold H₂O and DCM, then dried to afford the title compound (2.29 g, 74%). LCMS (ES⁺) *m/z*
20 313, 315 (M+H)⁺.

Step 2: 3-(4-bromo-3-methoxyphenyl)thiophene-2-carbonyl azide


A stirred solution of 3-(4-bromo-3-methoxyphenyl)thiophene-2-carboxylic acid (2.23 g, 7.13 mmol) in benzene (28.5 mL) was treated with triethylamine (1.39 mL, 9.98 mmol) and
25 diphenylphosphoryl azide (1.96 g, 7.13 mmol). The mixture was stirred for 20 h, then the volatiles were removed and the residue was purified by column chromatography on silica gel (eluent: toluene) to afford the title (1.63 g, 68 %). LCMS (ES⁺) *m/z* 310, 312 (M+H-N₂)⁺.

Step 3: 7-bromo-8-methoxythieno[2,3-*c*]isoquinolin-5-ol

30 A solution of 3-(4-bromo-3-methoxyphenyl)thiophene-2-carbonyl azide (530 mg, 1.57 mmol) was dissolved in diphenylmethane (10 mL) was stirred, and the temperature was raised gradually to 270 °C. Stirring was continued for 3 h then the mixture was cooled to 20 °C. The precipitate was collected by filtration then washed with diphenylmethane and hexane to afford the title compound (431 mg, 89%). LCMS (ES⁺) *m/z* 310, 312 (M+H)⁺.

35

Scheme 1



Example 1: (2*R*,4*S*,7*S*)-7-cyclohexyl-*N*-((1*R*,2*S*)-1-[(cyclopropylsulfonyl)amino]carbonyl}-2-vinylcyclopropyl)-12,12-dimethyl-6,9-dioxo-3,4,6,7,8,9,12,13,14,15-decahydro-2*H*,11*H*-16,18-(ethanediylidene)-2,5-methano[1,10,3,6]dioxadiazacyclononadecino[11,12-*b*]quinoline-4-carboxamide

Step 1: (9*Z*)-2-bromo-9*H*-fluoren-9-one oxime

To a solution of 2-bromo-9*H*-fluoren-9-one (100 mg, 0.39 mmol) in EtOH (10 mL) and water (3 mL) was added hydroxylamine hydrochloride (54 mg, 0.77 mmol). The mixture was then heated to reflux for 1 h. The solvent was then removed *in vacuo*, and to the residue was added aqueous NaHCO_3 . The solid was then filtered and dried to give the title product. LRMS $(\text{M}+\text{H})^+$ 274.2.

Step 2: 8-bromophenanthridin-6-ol

To the solid product from Step 1, (9Z)-2-bromo-9H-fluoren-9-one oxime (106 mg, 0.387 mmol) was added polyphosphoric acid (5 g). The mixture was then heated to 185 °C for 2 h. After cooling to r.t., water was added and the resulting solid was collected by filtration to give a 1:1 mixture of the title compounds and the regioisomeric 3-bromophenanthridin-6-ol. LRMS (M+H)⁺ = 274.2.

Step 3: 1-tert-butyl 2-methyl (2S,4R)-4-[(8-bromophenanthridin-6-yl)oxy]pyrrolidine-1,2-dicarboxylate

To a solution of the product mixture from Step 2 (176 mg, 0.642 mmol) in NMP (1.5 mL) was added 1-tert-butyl 2-methyl (2S,4S)-4-[[[4-bromophenyl)sulfonyl]oxy]pyrrolidine-1,2-dicarboxylate (373 mg, 0.803 mmol) and Cs₂CO₃ (418 mg, 1.29 mmol). The mixture was then heated to 60 °C for 18 h, and worked up with water and EtOAc. The organic layer was washed with brine, dried over MgSO₄, and the solvent was removed *in vacuo*. The crude material was purified on silica (gradient elution, 10-50% EtOAc/hex) to yield the title compound as a 1:1 mixture with the expected regioisomer. LRMS ((M-Boc)+H)⁺ = 401.2.

Step 4: 1-tert-butyl 2-methyl (2S,4R)-4-[(8-vinylphenanthridin-6-yl)oxy]pyrrolidine-1,2-dicarboxylate

To a degassed solution of the product mixture from Step 3 (320 mg, 0.64 mmol) in PhMe (5 mL) was added vinyltributyltin (0.225 mL, 0.77 mmol) and tetrakis(triphenylphosphine)palladium (74 mg, 0.06 mmol). The mixture was then heated to reflux for 18 h. The solvent was then removed *in vacuo* and the crude material was purified on silica (gradient elution, 5-50% EtOAc/hex) to provide the title compound as a 1:1 mixture with the expected regioisomer. LRMS ((M-Boc)+H)⁺ = 349.3.

Step 5: methyl (4R)-1-[(2S)-2-cyclohexyl-2-({[(2,2-dimethylpent-4-en-1-yl)oxy]carbonyl}amino)acetyl]-4-[(8-vinylphenanthridin-6-yl)oxy]-L-prolinate

To a solution of the product mixture from Step 4 (100 mg, 0.26 mmol) in DCM (5 mL) was bubbled HCl(g) for 10 min. After stirring for an additional 30 min, the solvent was removed *in vacuo* to yield methyl (4R)-4-[(8-vinylphenanthridin-6-yl)oxy]-L-prolinate hydrochloride, which was taken up in DCM (5 mL) and linker intermediate B20, (2S)-cyclohexyl({[(2,2-dimethylpent-4-en-1-yl)oxy]carbonyl}amino)acetic acid (85 mg, 0.29 mmol), TEA (0.073 mL, 0.52 mmol), EDC (63 mg, 0.33 mmol), and HOBt (50 mg, 0.33 mmol) were added. The mixture was stirred at r.t. for 18 h, the solvent was removed *in vacuo*, and the residue was taken up in EtOAc and extracted with NaHCO₃. The organic layer was dried over MgSO₄ and the solvent was removed *in vacuo*. The crude material was then purified on silica (gradient elution, 10-50% EtOAc/hex) to yield the title compound as a 1:1 mixture with the expected regioisomer. LRMS (M+H)⁺ = 628.4.

Step 6: methyl (2*R*,4*S*,7*S*,14*E*)-7-cyclohexyl-12,12-dimethyl-6,9-dioxo-3,4,6,7,8,9,12,13-octahydro-2*H*,11*H*-16,18-(ethanediylidene)-2,5-methano[1,10,3,6]dioxadiazacyclononadecino[11,12-*b*]quinoline-4-carboxylate

To a degassed solution of the mixture from Step 5 (100 mg, 0.16 mmol) in DCE (20 mL) was added the Zhan 1b catalyst (12 mg, 0.016 mmol) and the mixture was stirred at r.t. for 18 h. The solvent was then removed *in vacuo* and the crude material was purified on silica (gradient elution, 10-50% EtOAc/hex) to yield the title compound as a single isomer. LRMS (M+H)⁺ = 600.4.

Step 7: methyl (2*R*,4*S*,7*S*)-7-cyclohexyl-12,12-dimethyl-6,9-dioxo-3,4,6,7,8,9,12,13,14,15-decahydro-2*H*,11*H*-16,18-(ethanediylidene)-2,5-methano[1,10,3,6]dioxadiazacyclononadecino[11,12-*b*]quinoline-4-carboxylate

To a solution of the product from Step 6, methyl (2*R*,4*S*,7*S*,14*E*)-7-cyclohexyl-12,12-dimethyl-6,9-dioxo-3,4,6,7,8,9,12,13-octahydro-2*H*,11*H*-16,18-(ethanediylidene)-2,5-methano[1,10,3,6]dioxadiazacyclononadecino[11,12-*b*]quinoline-4-carboxylate (47 mg, 0.078 mmol) in EtOH (5 mL) was added Pd/C (10%, 4 mg). The mixture was then placed under a H₂ atmosphere (balloon pressure) and stirred for 18 h. The mixture was then filtered and the solvent was removed *in vacuo* to yield the title compound. LRMS (M+H)⁺ = 602.4.

Step 8: (2*R*,4*S*,7*S*)-7-cyclohexyl-12,12-dimethyl-6,9-dioxo-3,4,6,7,8,9,12,13,14,15-decahydro-2*H*,11*H*-16,18-(ethanediylidene)-2,5-methano[1,10,3,6]dioxadiazacyclononadecino[11,12-*b*]quinoline-4-carboxylic acid


To a solution of the product from Step 7, methyl (2*R*,4*S*,7*S*)-7-cyclohexyl-12,12-dimethyl-6,9-dioxo-3,4,6,7,8,9,12,13,14,15-decahydro-2*H*,11*H*-16,18-(ethanediylidene)-2,5-methano[1,10,3,6]dioxadiazacyclononadecino[11,12-*b*]quinoline-4-carboxylate (47 mg, 0.078 mmol) in THF (2 mL) and water (2 mL) was added LiOH (19 mg, 0.78 mmol). The mixture was then heated to 70 °C for 30 min and 1N HCl was then added to neutralize the base. The mixture was then extracted with EtOAc, the organic layer was dried over MgSO₄, and the solvent was removed *in vacuo* to yield the title compound. LRMS (M+H)⁺ = 588.5.

Step 9: (2*R*,4*S*,7*S*)-7-cyclohexyl-*N*-((1*R*,2*S*)-1-[(cyclopropylsulfonyl)amino]carbonyl)-2-vinylcyclopropyl-12,12-dimethyl-6,9-dioxo-3,4,6,7,8,9,12,13,14,15-decahydro-2*H*,11*H*-16,18-(ethanediylidene)-2,5-methano[1,10,3,6]dioxadiazacyclononadecino[11,12-*b*]quinoline-4-carboxamide

To a solution of the product from Step 8, (2*R*,4*S*,7*S*)-7-cyclohexyl-12,12-dimethyl-6,9-dioxo-3,4,6,7,8,9,12,13,14,15-decahydro-2*H*,11*H*-16,18-(ethanediylidene)-2,5-methano[1,10,3,6]dioxadiazacyclononadecino[11,12-*b*]quinoline-4-carboxylic acid (45 mg, 0.077 mmol) in DMF (1 mL) was added acylsulfonamide intermediate A1 (27 mg, 0.1 mmol), DIPEA (0.04 mL, 0.23 mmol), and HATU (38 mg, 0.1 mmol). After 20 min, the mixture was purified

directly by reverse phase chromatography (100x30 mm, 40-95% ACN/0.15% aq. TFA) to give the title compound as a white solid. LRMS $(M+H)^+ = 800.6$.

Scheme 2



5

Example 2: (2*R*,4*S*,7*S*,14*E*)-21-cyano-7-cyclopentyl-*N*-((1*R*,2*S*)-1-
 {[(cyclopropylsulfonyl)amino]carbonyl}-2-vinylcyclopropyl)-25-methoxy-12,12-dimethyl-6,9-
 dioxo-3,4,6,7,8,9,12,13-octahydro-2*H*,11*H*-16,18-(ethanediylidene)-2,5-
 methano[1,10,3,6]dioxadiazacyclononadecino[11,12-*b*]quinoline-4-carboxamide

10

Step 1: 1-tert-butyl 2-methyl (2S,4R)-4-[(8-bromo-3-cyano-9-methoxyphenanthridin-6-yl)oxy]pyrrolidine-1,2-dicarboxylate

To a solution of 8-bromo-9-methoxy-6-oxo-5,6-dihydrophenanthridine-3-carbonitrile (C1), 8-bromo-9-methoxy-6-oxo-5,6-dihydrophenanthridine-3-carbonitrile (354 mg, 1.07 mmol) in NMP (10 mL) was added 1-tert-butyl 2-methyl (2S,4S)-4-[(4-bromophenyl)sulfonyl]oxy}pyrrolidine-1,2-dicarboxylate (549 mg, 1.18 mmol) and Cs₂CO₃ (876 mg, 2.69 mmol). The mixture was then heated to 60 °C for 18 h, and worked up with water and EtOAc. The organic layer was washed with brine, dried over MgSO₄, and the solvent was removed *in vacuo*. The crude material was purified on silica (gradient elution, 10-50% EtOAc/hex) to yield the title compound. LRMS ((M-Boc)+H)⁺ = 456.2.

Step 2: methyl (4R)-4-[(8-bromo-3-cyano-9-methoxyphenanthridin-6-yl)oxy]-1-[(2S)-2-cyclopentyl-2-({[(2,2-dimethylpent-4-en-1-yl)oxy]carbonyl}amino)acetyl]-L-prolinate

To a solution of the product mixture from Step 1, 1-tert-butyl 2-methyl (2S,4R)-4-[(8-bromo-3-cyano-9-methoxyphenanthridin-6-yl)oxy]pyrrolidine-1,2-dicarboxylate (419 mg, 0.75 mmol) in DCM (10 mL) was bubbled HCl(g) for 20 min. After stirring for an additional 30 min, the solvent was removed *in vacuo* to yield methyl (4R)-4-[(8-bromo-3-cyano-9-methoxyphenanthridin-6-yl)oxy]-L-prolinate hydrochloride, which was taken up in DCM (5 mL) and linker intermediate B21, (2S)-cyclopentyl({[(2,2-dimethylpent-4-en-1-yl)oxy]carbonyl}amino)acetic acid (234 mg, 0.83 mmol), TEA (0.314 mL, 2.25 mmol), EDC (187 mg, 0.98 mmol), and HOBT (149 mg, 0.98 mmol) were added. The mixture was stirred at r.t. for 18 h, the solvent was removed *in vacuo*, and the residue was taken up in EtOAc and extracted with NaHCO₃. The organic layer was dried over MgSO₄ and the solvent was removed *in vacuo*. The crude material was then purified on silica (gradient elution, 0-10% EtOAc/MeOH/NH₃) to yield the title compound. LRMS (M+H)⁺ = 721.4.

Step 3: methyl (4R)-4-[(3-cyano-9-methoxy-8-vinylphenanthridin-6-yl)oxy]-1-[(2S)-2-cyclopentyl-2-({[(2,2-dimethylpent-4-en-1-yl)oxy]carbonyl}amino)acetyl]-L-prolinate

To a degassed solution of the product mixture from Step 2, methyl (4R)-4-[(8-bromo-3-cyano-9-methoxyphenanthridin-6-yl)oxy]-1-[(2S)-2-cyclopentyl-2-({[(2,2-dimethylpent-4-en-1-yl)oxy]carbonyl}amino)acetyl]-L-prolinate (420 mg, 0.58 mmol) in PhMe (10 mL) was added vinyltributyltin (0.205 mL, 0.70 mmol) and tetrakis(triphenylphosphine)palladium (67 mg, 0.06 mmol). The mixture was then heated to reflux for 18 h. The solvent was then removed *in vacuo* and the crude material was purified on silica (gradient elution, 10-50% EtOAc/hex) to provide the title compound. LRMS (M+H)⁺ = 669.3.

Step 4: methyl (2*R*,4*S*,7*S*,14*E*)-21-cyano-7-cyclopentyl-25-methoxy-12,12-dimethyl-6,9-dioxo-3,4,6,7,8,9,12,13-octahydro-2*H*,11*H*-16,18-(ethanediylidene)-2,5-methano[1,10,3,6]dioxadiazacyclononadecino[11,12-*b*]quinoline-4-carboxylate

To a degassed solution of the mixture from Step 3, methyl (4*R*)-4-[(3-cyano-9-methoxy-8-vinylphenanthridin-6-yl)oxy]-1-[(2*S*)-2-cyclopentyl-2-({[(2,2-dimethylpent-4-en-1-yl)oxy]carbonyl}amino)acetyl]-L-prolinate (306 mg, 0.45 mmol) in DCE (60 mL) was added the Zhan 1b catalyst (33 mg, 0.05 mmol) and the mixture was stirred at 70 °C for 2 h. The solvent was then removed *in vacuo* and the crude material was purified on silica (gradient elution, 10-50% EtOAc/hex) to yield the title compound. LRMS (M+H)⁺ = 641.4.

Step 5: (2*R*,4*S*,7*S*,14*E*)-21-cyano-7-cyclopentyl-25-methoxy-12,12-dimethyl-6,9-dioxo-3,4,6,7,8,9,12,13-octahydro-2*H*,11*H*-16,18-(ethanediylidene)-2,5-methano[1,10,3,6]dioxadiazacyclononadecino[11,12-*b*]quinoline-4-carboxylic acid

To a solution of the product from Step 4, methyl (2*R*,4*S*,7*S*,14*E*)-21-cyano-7-cyclopentyl-25-methoxy-12,12-dimethyl-6,9-dioxo-3,4,6,7,8,9,12,13-octahydro-2*H*,11*H*-16,18-(ethanediylidene)-2,5-methano[1,10,3,6]dioxadiazacyclononadecino[11,12-*b*]quinoline-4-carboxylate (277 mg, 0.43 mmol) in THF (5 mL) and water (5 mL) was added LiOH (155 mg, 6.48 mmol). The mixture was then heated to 65 °C for 30 min and 1N HCl was then added to neutralize the base. The mixture was then extracted with EtOAc, the organic layer was dried over MgSO₄, and the solvent was removed *in vacuo* to yield the title compound. LRMS (M+H)⁺ = 627.4.

Step 6: (2*R*,4*S*,7*S*,14*E*)-21-cyano-7-cyclopentyl-*N*-((1*R*,2*S*)-1-{{[(cyclopropylsulfonyl)amino]carbonyl}-2-vinylcyclopropyl)-25-methoxy-12,12-dimethyl-6,9-dioxo-3,4,6,7,8,9,12,13-octahydro-2*H*,11*H*-16,18-(ethanediylidene)-2,5-methano[1,10,3,6]dioxadiazacyclononadecino[11,12-*b*]quinoline-4-carboxamide

To a solution of the product from Step 5, (2*R*,4*S*,7*S*,14*E*)-21-cyano-7-cyclopentyl-25-methoxy-12,12-dimethyl-6,9-dioxo-3,4,6,7,8,9,12,13-octahydro-2*H*,11*H*-16,18-(ethanediylidene)-2,5-methano[1,10,3,6]dioxadiazacyclononadecino[11,12-*b*]quinoline-4-carboxylic acid (80 mg, 0.13 mmol) in DMF (2 mL) was added acylsulfonamide intermediate A1 (43 mg, 0.16 mmol), DIPEA (0.067 mL, 0.38 mmol), and HATU (68 mg, 0.18 mmol). After 30 min, the mixture was purified directly by reverse phase chromatography (100x30 mm, 40-95% ACN/0.15% aq. TFA) to give the title compound as a white solid. LRMS (M+H)⁺ = 839.4.

Example 3: (2*R*,4*S*,7*S*)-21-cyano-7-cyclopentyl-*N*-((1*R*,2*S*)-1-{{[(cyclopropylsulfonyl)amino]carbonyl}-2-vinylcyclopropyl)-25-methoxy-12,12-dimethyl-6,9-dioxo-3,4,6,7,8,9,12,13,14,15-decahydro-2*H*,11*H*-16,18-(ethanediylidene)-2,5-methano[1,10,3,6]dioxadiazacyclononadecino[11,12-*b*]quinoline-4-carboxamide

Step 1: (2R,4S,7S)-21-cyano-7-cyclopentyl-25-methoxy-12,12-dimethyl-6,9-dioxo-3,4,6,7,8,9,12,13,14,15-decahydro-2H,11H-16,18-(ethanediylidene)-2,5-methano[1,10,3,6]dioxadiazacyclononadecino[11,12-b]quinoline-4-carboxylic acid

To a solution of (2R,4S,7S,14E)-21-cyano-7-cyclopentyl-25-methoxy-12,12-dimethyl-6,9-dioxo-3,4,6,7,8,9,12,13-octahydro-2H,11H-16,18-(ethanediylidene)-2,5-methano[1,10,3,6]dioxadiazacyclononadecino[11,12-b]quinoline-4-carboxylic acid (Example 2, Step 5, 130 mg, 0.207 mmol) in THF (10 mL) was added Pd/C (10%, 13 mg). The mixture was then placed under a H₂ atmosphere (balloon pressure) and stirred for 2 h. The mixture was then filtered and the solvent was removed *in vacuo* to yield the title compound. LRMS (M+H)⁺ = 629.4.

Step 2: (2R,4S,7S)-21-cyano-7-cyclopentyl-N-((1R,2S)-1-{{[(cyclopropylsulfonyl)amino]carbonyl}-2-vinylcyclopropyl)-25-methoxy-12,12-dimethyl-6,9-dioxo-3,4,6,7,8,9,12,13,14,15-decahydro-2H,11H-16,18-(ethanediylidene)-2,5-methano[1,10,3,6]dioxadiazacyclononadecino[11,12-b]quinoline-4-carboxamide

To a solution of the product from Step 1, (2R,4S,7S)-21-cyano-7-cyclopentyl-25-methoxy-12,12-dimethyl-6,9-dioxo-3,4,6,7,8,9,12,13,14,15-decahydro-2H,11H-16,18-(ethanediylidene)-2,5-methano[1,10,3,6]dioxadiazacyclononadecino[11,12-b]quinoline-4-carboxylic acid (130 mg, 0.21 mmol) in DMF (2 mL) was added acylsulfonamide intermediate A1 (69 mg, 0.26 mmol), DIPEA (0.11 mL, 0.62 mmol), and HATU (110 mg, 0.29 mmol). After 30 min, the mixture was purified directly by reverse phase chromatography (100x30 mm, 40-95% ACN/0.15% aq. TFA) to give the title compound as a white solid. LRMS (M+H)⁺ = 841.6.

Example 4: (3R,5S,8S)-8-cyclohexyl-N-((1R,2S)-1-{{[(cyclopropylsulfonyl)amino]carbonyl}-2-vinylcyclopropyl)-18-methoxy-13,13-dimethyl-7,10-dioxo-2,11-dioxo-6,9,27-triazapentacyclo[15.10.2.1^{3,6}.0^{20,28}.0^{21,26}]triaconta-1(27),15,17,19,21(26),28-hexaene-5-carboxamide

Step 1: (4R)-4-[(8-bromo-9-methoxy-1,2,3,4-tetrahydrophenanthridin-6-yl)oxy]-1-(tert-butoxycarbonyl)-L-proline

To a solution of (4R)-1-(tert-butoxycarbonyl)-4-hydroxy-L-proline (639 mg, 2.76 mmol) in DMSO (10 mL) was added KOtBu (873 mg, 7.78 mmol) at r.t. The temperature rose to 32 °C and the reaction was stirred for 30 min. The solution was cooled to ~13 °C and the intermediate C8, 8-bromo-6-chloro-9-methoxy-1,2,3,4-tetrahydrophenanthridine (820 mg, 2.51 mmol) was added in 8 mL of DMSO slurry) over 5 min. The ice bath was removed and the mixture was allowed to stir for 1 h. The reaction was slowly quenched into a well-stirred mixture of aqueous citric acid (150 mL) and allowed to stir at r.t. for 30 min. The resulting solids were filtered, dissolved with EtOAc, washed with H₂O/KHSO₄, dried over Na₂SO₄, and the solvent was removed *in vacuo* to yield the title compound. LRMS (M+H)⁺ = 520.9.

Step 2: ethyl (4R)-4-[(8-bromo-9-methoxy-1,2,3,4-tetrahydrophenanthridin-6-yl)oxy]-L-prolinate hydrochloride

To a solution of the product from Step 1, (4R)-4-[(8-bromo-9-methoxy-1,2,3,4-tetrahydrophenanthridin-6-yl)oxy]-1-(*tert*-butoxycarbonyl)-L-proline (500 mg, 0.96 mmol) in EtOH (80 mL) was bubbled HCl (g) for 30 min. The mixture was then stirred for 2 days at r.t. and then the solvent was removed *in vacuo* to yield the title compound. LRMS (M+H)⁺ = 448.9.

Step 3: ethyl (4R)-4-[(8-bromo-9-methoxy-1,2,3,4-tetrahydrophenanthridin-6-yl)oxy]-1-[(2S)-2-cyclohexyl-2-({[(2,2-dimethylpent-4-en-1-yl)oxy]carbonyl}amino)acetyl]-L-prolinate

To a solution of the product from Step 2, ethyl (4R)-4-[(8-bromo-9-methoxy-1,2,3,4-tetrahydrophenanthridin-6-yl)oxy]-L-prolinate hydrochloride (466 mg, 0.96 mmol) in DMF (8 mL) was added linker intermediate B20, (2S)-cyclohexyl({[(2,2-dimethylpent-4-en-1-yl)oxy]carbonyl}amino)acetic acid (300 mg, 1.0 mmol), DIPEA (0.50 mL, 2.88 mmol), HATU (547 mg, 1.44 mmol), and DMAP (59 mg, 0.48 mmol) were added. The mixture was stirred at r.t. for 18 h and then the mixture was poured into 120 mL of aqueous citric acid. The resulting solid was removed by filtration and washed with water. The solid was then dissolved in EtOAc, dried over Na₂SO₄, and the solvent was removed *in vacuo*. The crude material was then purified on silica (gradient elution, 20-50% EtOAc/hexanes) to yield the title compound. LRMS (M+H)⁺ = 728.0.

Step 4: (3R,5S,8S)-8-cyclohexyl-18-methoxy-13,13-dimethyl-7,10-dioxo-2,11-dioxa-6,9,27-triazapentacyclo[15.10.2.1^{3,6}.0^{20,28}.0^{21,26}]triaconta-1(27),15,17,19,21(26),28-hexaene-5-carboxylic acid

Using the product from Step 3, ethyl (4R)-4-[(8-bromo-9-methoxy-1,2,3,4-tetrahydrophenanthridin-6-yl)oxy]-1-[(2S)-2-cyclohexyl-2-({[(2,2-dimethylpent-4-en-1-yl)oxy]carbonyl}amino)acetyl]-L-prolinate, the title compound was prepared according to Example 2, Steps 6-8. LRMS (M+H)⁺ = 620.0.

Step 5: (3R,5S,8S)-8-cyclohexyl-N-((1R,2S)-1-[(cyclopropylsulfonyl)amino]carbonyl)-2-vinylcyclopropyl)-18-methoxy-13,13-dimethyl-7,10-dioxo-2,11-dioxa-6,9,27-triazapentacyclo[15.10.2.1^{3,6}.0^{20,28}.0^{21,26}]triaconta-1(27),15,17,19,21(26),28-hexaene-5-carboxamide

Using the product from Step 4, (3R,5S,8S)-8-cyclohexyl-18-methoxy-13,13-dimethyl-7,10-dioxo-2,11-dioxa-6,9,27-triazapentacyclo[15.10.2.1^{3,6}.0^{20,28}.0^{21,26}]triaconta-1(27),15,17,19,21(26),28-hexaene-5-carboxylic acid, the title compound was prepared according to Step 9, Example 2. LRMS (M+H)⁺ = 832.2.

Example 5: (3*R*,5*S*,8*S*)-8-cyclohexyl-*N*-((1*R*,2*S*)-1-{[(cyclopropylsulfonyl)amino]carbonyl}-2-vinylcyclopropyl)-18-methoxy-13,13-dimethyl-7,10-dioxo-2,11-dioxo-6,9,27-triazapentacyclo[15.10.2.1^{3,6}.0^{20,28}.0^{21,26}]triaconta-1(27),17,19,21(26),28-pentaene-5-carboxamide

Using the product from Step 4, Example 4, (3*R*,5*S*,8*S*)-8-cyclohexyl-18-methoxy-13,13-dimethyl-7,10-dioxo-2,11-dioxo-6,9,27-triazapentacyclo[15.10.2.1^{3,6}.0^{20,28}.0^{21,26}]triaconta-1(27),15,17,19,21(26),28-hexaene-5-carboxylic acid, the title compound was prepared according to Example 3, Steps 1-2. LRMS (M+H)⁺ = 834.2.

The following examples were prepared using a procedure similar to that described for Examples 2 and 3, starting with the appropriate intermediates A, B, and C indicated.

Compounds in Table 1 having a basic group or acidic group are depicted and named as the free base or acid. Depending on the reaction and purification conditions, various compounds in Table 1 having a basic group were isolated in either the free base form, or as a salt (such as HCl salt), or in both free base and salt forms. Various compounds in the table having an acid group were isolated in either the acid form, or as a salt (such as Na salt), or in both acid and salt forms.

Ex.	Name	LRMS (M+H) ⁺	Proce- dure	Inter- mediat es
6	(2 <i>R</i> ,4 <i>S</i> ,7 <i>S</i>)-7-cyclopentyl- <i>N</i> -((1 <i>R</i> ,2 <i>S</i>)-1-{[(cyclopropylsulfonyl)amino]carbonyl}-2-vinylcyclopropyl)-25-methoxy-12,12-dimethyl-6,9-dioxo-3,4,6,7,8,9,12,13,14,15-decahydro-2 <i>H</i> ,11 <i>H</i> -16,18-(ethanediylidene)-2,5-methano[1,10,3,6]dioxadiazacyclononadecino[11,12- <i>b</i>]quinoline-4-carboxamide	816.4	3	B21, C3, A1
7	(2 <i>R</i> ,4 <i>S</i> ,7 <i>S</i>)-7-cyclopentyl- <i>N</i> -((1 <i>R</i> ,2 <i>S</i>)-1-{[(cyclopropylsulfonyl)amino]carbonyl}-2-vinylcyclopropyl)-25-methoxy-12,12,21-trimethyl-6,9-dioxo-3,4,6,7,8,9,12,13,14,15-decahydro-2 <i>H</i> ,11 <i>H</i> -16,18-etheno-2,5-methano[1,10,3,6]dioxadiazacyclononadecino[11,12- <i>b</i>]quinoline-4-carboxamide	830.3	3	C4, B21, A1
8	(2 <i>R</i> ,4 <i>S</i> ,7 <i>S</i> ,14 <i>E</i>)-7-cyclohexyl- <i>N</i> -((1 <i>R</i> ,2 <i>S</i>)-1-{[(cyclopropylsulfonyl)amino]carbonyl}-2-vinylcyclopropyl)-25-methoxy-10,12,12-trimethyl-6,9-dioxo-3,4,6,7,8,9,10,11,12,13-decahydro-2 <i>H</i> -16,18-etheno-2,5-methano[1,5,8,10]oxatriazacyclo nonadecino[19,18- <i>b</i>]quinoline-4-carboxamide	841.3	2	C3, B27, A1
9	(2 <i>R</i> ,4 <i>S</i> ,7 <i>S</i> ,14 <i>Z</i>)-7-cyclohexyl- <i>N</i> -((1 <i>R</i> ,2 <i>S</i>)-1-{[(cyclopropylsulfonyl)amino]carbonyl}-2-vinylcyclopropyl)-25-methoxy-10,12,12-trimethyl-6,9-dioxo-3,4,6,7,8,9,10,11,12,13-decahydro-2 <i>H</i> -16,18-	841.3	2	C3, B27, A1

	etheno-2,5-methano [1,5,8,10]oxatriazacyclononadecino[19,18-b]quinoline-4-carboxamide			
10	(2R,4S,7S)-7-cyclohexyl-N-((1R,2S)-1-{{[(cyclopropylsulfonyl)amino]carbonyl}-2-vinylcyclopropyl)-25-methoxy-10,12,12-trimethyl-6,9-dioxo-3,4,6,7,8,9,10,11,12,13,14,15-dodecahydro-2H-16,18-etheno-2,5-methano[1,5,8,10]oxatriazacyclononadecino[19,18-b]quinoline-4-carboxamide	843.4	3	C3, B27, A1
11	(3aR,7S,10S,12R,24aR)-7-cyclohexyl-N-((1R,2S)-1-{{[(cyclopropylsulfonyl)amino]carbonyl}-2-vinylcyclopropyl)-25-methoxy-5,8-dioxo-1,2,3,3a,5,6,7,8, 11,12,22,23,24,24a-tetradecahydro-10H-19,21-etheno-9,12-methanocyclopenta[18,19][1,10,3,6]dioxadiazacyclononadecino[11,12-b]quinoline-10-carboxamide	842.3	3 Separa te	C3, B22, A1
12	(3aS,7S,10S,12R,24aS)-7-cyclohexyl-N-((1R,2S)-1-{{[(cyclopropylsulfonyl)amino]carbonyl}-2-vinylcyclopropyl)-25-methoxy-5,8-dioxo-1,2,3,3a,5,6,7,8, 11,12,22,23,24,24a-tetradecahydro-10H-19,21-etheno-9,12-methanocyclopenta[18,19][1,10,3,6]dioxadiazacyclononadecino[11,12-b]quinoline-10-carboxamide	842.3	3 Separa te	C3, B22, A1
13	(2R,4S,7S,14E)-20-chloro-7-cyclopentyl-N-((1R,2S)-1-{{[(cyclopropylsulfonyl)amino]carbonyl}-2-vinylcyclo propyl)-25-methoxy-12,12-dimethyl-6,9-dioxo-3,4,6,7,8,9,12,13-octahydro-2H,11H-16,18-etheno-2,5-methano [1,10,3,6]dioxadiazacyclononadecino[11,12-b]quinoline-4-carboxamide	848.4	2	C6, B21, A1
14	(2R,4S,7S)-20-chloro-7-cyclopentyl-N-((1R,2S)-1-{{[(cyclopropylsulfonyl)amino]carbonyl}-2-vinylcyclopropyl)-25-methoxy-12,12-dimethyl-6,9-dioxo-3,4,6,7,8,9,12,13,14,15-decahydro-2H,11H-16,18-etheno-2,5-methano[1,10,3,6]dioxadiazacyclononadecino[11,12-b]quinoline-4-carboxamide	850.3	3	C6, B21, A1
15	(2R,4S,7S)-7-cyclopentyl-N-((1R,2S)-1-{{[(cyclopropylsulfonyl)amino]carbonyl}-2-vinylcyclopropyl)-21-fluoro-25-methoxy-12,12-dimethyl-6,9-dioxo-3,4,6,7,8,9,12,13,14,15-decahydro-2H,11H-16,18-(ethanediylidene)-2,5-methano[1,10,3,6]dioxadiaza cyclononadecino[11,12-b]quinoline-4-carboxamide	834.3	3	C5, B21, A1
16	(2R,4S,7S,14E)-7-cyclopentyl-N-((1R,2S)-1-{{[(cyclopropylsulfonyl)	844.5	2	C2,

	amino]carbonyl}-2-vinylcyclopropyl)-21,25-dimethoxy-12,12-dimethyl-6,9-dioxo-3,4,6,7,8,9,12,13-octahydro-2H,11H-16,18-(ethanediylidene)-2,5-methano[1,10,3,6]dioxadiazacyclononadecino[11,12-b]quinoline-4-carboxamide			B21, A1
17	(2R,4S,7S)-7-cyclopentyl-N-((1R,2S)-1-[[cyclopropylsulfonyl]amino]carbonyl}-2-vinylcyclopropyl)-21,25-dimethoxy-12,12-dimethyl-6,9-dioxo-3,4,6,7,8,9,12,13, 14,15-decahydro-2H,11H-16,18-(ethanediylidene)-2,5-methano[1,10,3,6]dioxadiazacyclononadecino[11,12-b]quinoline-4-carboxamide	846.4	3	C2, B21, A1
18	(3R,5S,8S)-8-cyclopentyl-N-((1R,2S)-1-[[cyclopropylsulfonyl]amino]carbonyl}-2-vinylcyclopropyl)-26-ethoxy-13,13-dimethyl-7,10-dioxo-2,11-dioxo-6,9,25-triazapentacyclo[15.10.2.13,6.018,23.024,28]triaconta-1(27),15,17,19,21,23,25,28-octaene-5-carboxamide	828.4	2	C7, B21, A1
19	(3R,5S,8S)-8-tert-butyl-N-((1R,2S)-1-[[cyclopropylsulfonyl]amino]carbonyl}-2-vinylcyclopropyl)-18-methoxy-13,13-dimethyl-7,10-dioxo-2,11-dioxo-6,9,27-triazapentacyclo[15.10.2.13,6.020,28.021,26]triaconta-1(27),15,17,19,21(26),28-hexaene-5-carboxamide	806.1	4	C8, B23, A1
20	(3R,5S,8S)-8-cyclohexyl-N-((1R,2R)-1-[[cyclopropylsulfonyl]amino]carbonyl}-2-ethylcyclopropyl)-18-methoxy-13,13-dimethyl-7,10-dioxo-2,11-dioxo-6,9,27-triazapentacyclo[15.10.2.13,6.020,28.021,26]triaconta-1(27),17,19,21(26),28-pentaene-5-carboxamide	836.2	5	C8, B20, A3
21	(3R,5S,8S)-8-cyclohexyl-N-((1R,2R)-1-[[cyclopropylsulfonyl]amino]carbonyl}-2-ethylcyclopropyl)-18-methoxy-13,13-dimethyl-7,10-dioxo-2,11-dioxo-6,9,27-triazapentacyclo[15.10.2.13,6.020,28.021,26]triaconta-1(27),15,17,19,21(26),28-hexaene-5-carboxamide	834.2	4	C8, B20, A3
22	(3R,5S,8S)-8-cyclohexyl-N-((1R,2S)-1-[[cyclopropylsulfonyl]amino]carbonyl}-2-vinylcyclopropyl)-18-methoxy-13,13-dimethyl-7,10-dioxo-2,11-dioxo-6,9,26-triazapentacyclo[15.9.2.13,6.020,27.021,25]nonacosa-1(26),17,19, 21(25),27-pentaene-5-carboxamide	820.1	5	C9, B20, A1
23	(2R,4S,7S,14E)-7-cyclohexyl-N-((1R,2S)-1-[[cyclopropylsulfonyl]amino]carbonyl}-2-vinylcyclopropyl)-24-methoxy-12,12-dimethyl-6,9-dioxo-3,4,6,7,8,9,12,13-octahydro-2H,11H-16,18-etheno-2,5-methanothieno[3',2':5,6]pyrido[2,3-	834	2	A1, B20, C12

	k][1,10,3,6]dioxadiazacyclononadecine-4-carboxamide			
24	(2R,4S,7S)-7-cyclohexyl-N-((1R,2S)-1-{{[(cyclopropylsulfonyl) amino]carbonyl}-2-vinylcyclopropyl)-24-methoxy-12,12-dimethyl-6,9-dioxo-3,4,6,7,8,9,12,13,14,15-decahydro-2H,11H-16,18-etheno-2,5-methano thieno[3',2':5,6]pyrido[2,3-k][1,10,3,6]dioxadiazacyclononadecine-4-carboxamide	836	2 (steps 1-4) then 3	A2, B20, C12
25	(2R,4S,7S,14E)-7-butyl-N-((1R,2S)-1-{{[(cyclopropylsulfonyl) amino] carbonyl}-2-vinylcyclopropyl)-24-methoxy-12,12-dimethyl-6,9-dioxo-3,4,6,7,8,9,12,13-octahydro-2H,11H-16,18-(ethanediylidene)-2,5-methanothieno[3',2':5,6]pyrido [2,3-k][1,10,3,6]dioxadiazacyclo nonadecine-4-carboxamide	808.4	2	A1, B24, C12
26	(2R,4S,7S,14E)-7-cyclopentyl-N-((1R,2S)-1-{{[(cyclopropylsulfonyl) amino]carbonyl}-2-vinylcyclopropyl)-24-methoxy-12,12-dimethyl-6,9-dioxo-3,4,6,7,8,9,12,13-octahydro-2H,11H-16,18-(ethanediylidene)-2,5-methanothieno[3',2':5,6]pyrido [2,3-k][1,10,3,6]dioxadiazacyclo nonadecine-4-carboxamide	820.4	2	A1, B21, C12
27	(2R,4S,7S,14E)-7-tert-butyl-N-((1R,2S)-1-{{[(cyclopropylsulfonyl) amino]carbonyl}-2-vinylcyclopropyl)-24-methoxy-12,12-dimethyl-6,9-dioxo-3,4,6,7,8,9,12,13-octahydro-2H,11H-16,18-(ethanediylidene)-2,5-methanothieno[3',2':5,6]pyrido [2,3-k][1,10,3,6]dioxadiazacyclo nonadecine-4-carboxamide	808.4	2	A1, B23, C12
28	(4E,13S,16S,18R)-13-tert-butyl-N-((1R,2S)-1-{{[(cyclopropylsulfonyl) amino]carbonyl}-2-vinylcyclopropyl)-1,8,8-trimethyl-11,14-dioxo-6,7,8,9,11,12,13,14, 17,18-decahydro-3H,16H-15,18-methano-10,19-dioxo-2a,12,15,20-tetraazabenzo[g]cycloicosa[1,2,3-cd]indene-16-carboxamide	803.6	2 (omit step 3)	A1, B13, C10
29	(13S,16S,18R)-13-tert-butyl-N-((1R,2S)-1-{{[(cyclopropylsulfonyl) amino]carbonyl}-2-vinylcyclo propyl)-1,8,8-trimethyl-11,14-dioxo-4,5,6,7,8,9,11,12,13,14,17,18-dodecahydro-3H,16H-15,18-methano-10,19-dioxo-2a,12,15,20-tetraazabenzo[g]cycloicosa[1,2,3-cd]indene-16-carboxamide	805.6	2 (steps 1,2, 4) then 3	A1, B13, C10
30	(4E,12S,15S,17R)-12-tert-butyl-N-((1R,2S)-1-{{[(cyclopropylsulfonyl) amino]carbonyl}-2-vinylcyclo propyl)-1,7,7-trimethyl-10,13-dioxo-3,6,7,8,10,11,12,13,16,17-decahydro-15H-14,17-methano-9,18-dioxo-2a,11,14,19-tetraazabenzo[g]cyclononadeca[1,2,3-cd]indene-15-carboxamide	789.7	2 (omit step 3)	A1, B23, C10
31	(4E,14S,17S,19R)-14-cyclopentyl-N-((1R,2S)-1-{{[(cyclopropylsulfonyl) amino]carbonyl}-2-vinylcyclopropyl)-1,9,9-	830	2 (omit	A1, B25,

	trimethyl-12,15-dioxo-3,6,7,8,9,10,12,13,14, 15,18,19-dodecahydro-17H-16,19-methano-11,20-dioxa-2a,13,16,21-tetraazabenzog[cyclohenicosa[1,2,3-cd]indene-17-carboxamide		step 3)	C10
32	(4E,14S,17S,19R)-14-cyclopentyl-N-((1R,2S)-1- {[(cyclopropylsulfonyl) amino]carbonyl}-2-vinylcyclo propyl)-1,11-dimethyl-12,15-dioxo-6,7,8,9,10,11,12,13,14,15,18,19-dodecahydro-3H,17H-16,19-methano-20-oxa-2a,11,13,16,21-pentaazabenzog[cyclohenicosa[1,2,3-cd]indene-17-carboxamide	815	2 (omit step 3)	A1, B28, C10
33	(14S,17S,19R)-14-cyclopentyl-N-((1R,2S)-1- {[(cyclopropylsulfonyl) amino]carbonyl}-2-vinylcyclopropyl)-1,9,9-trimethyl-12,15-dioxo-3,4,5,6,7,8,9,10,12,13, 14,15,18,19-tetradecahydro-17H-16,19-methano-11,20-dioxa-2a,13,16,21-tetraazabenzog[cyclohenicosa[1,2,3-cd]indene-17-carboxamide	832	2 (steps 1,2, 4) then 3	A1, B25, C10
34	(14S,17S,19R)-14-cyclopentyl-N-((1R,2S)-1- {[(cyclopropylsulfonyl) amino]carbonyl}-2-vinylcyclopropyl)-1,11-dimethyl-12,15-dioxo-4,5,6,7,8,9,10,11,12,13,14,15,18,19-tetradecahydro-3H,17H-16,19-methano-20-oxa-2a,11,13,16,21-pentaazabenzog[cyclohenicosa[1,2,3-cd]indene-17-carboxamide	817	2 (steps 1,2, 4) then 3	A1, B28, C10
35	(12S,15S,17R)-12-tert-butyl-N-((1R,2S)-1- {[(cyclopropylsulfonyl) amino]carbonyl}-2-vinylcyclopropyl)-1,7,7-trimethyl-10,13-dioxo-3,4,5,6,7,8,10,11,12, 13,16,17-dodecahydro-15H-14,17-methano-9,18-dioxa-2a,11,14,19-tetraazabenzog[cyclononadeca[1,2,3-cd]indene-15-carboxamide	791	2 (steps 1,2, 4) then 3	A1, B23, C10
36	(4E,13S,16S,18R)-13-tert-butyl-N-((1R,2S)-1- {[(cyclopropylsulfonyl) amino]carbonyl}-2-vinylcyclo propyl)-22-methoxy-1,8,8-trimethyl-11,14-dioxo-6,7,8,9,11,12,13,14, 17,18-decahydro-3H,16H-15,18-methano-10,19-dioxa-2a,12,15,20-tetraazabenzog[cycloicosa[1,2,3-cd]indene-16-carboxamide	834	2 (omit step 3)	A1, B13, C11
37	(3R,5S,8S)-8-cyclopentyl-N-((1R,2S)-1- {[(cyclopropylsulfonyl) amino]carbonyl}-2-vinylcyclopropyl)-26-ethoxy-13,13-dimethyl-7,10-dioxo-2,11-dioxa-6,9,25-triazapentacyclo[15.10.2.13,6.018,23.024,28]triaconta-1(27),17,19,21, 23,25,28-heptaene-5-carboxamide	830.5	3	C7, B21, A1

Example 38: (3R,5S,8S)-8-cyclohexyl-N-((1R,2S)-1-
{[(cyclopropylsulfonyl) amino]carbonyl}-2-vinylcyclopropyl)-18-methoxy-13,13-dimethyl-7,10-dioxo-2,11-dioxa-6,9,21,24-tetraazapentacyclo[15.9.2.1^{3,6}.0^{20,27}.0^{21,25}]nonacosa-1(26),17,19,22,24,27-hexaene-5-carboxamide

Step 1: 6-Bromo-4-hydroxy-7-methoxyquinolin-2(1H)-one

To a mixture of 4-bromo-3-methoxyaniline (10 g, 49.5 mmol) and malonic acid (5.15 g, 49.5 mmol) was added POCl₃ (5.07 ml, 54.4 mmol) with thorough mixing, and it was then heated to 105 °C. After 5 min, the reaction began to bubble vigorously, and eventually formed a hard foam and heating was continued for 1 h. After cooling, water (200 mL) was added and the mixture was stirred for 30 min. The solid was filtered off and washed with water. To the solid was added 2N NaOH (300 mL) and stirring was continued overnight. The remaining solid was filtered off, and EtOH (5 mL) was then added to the filtrate and the basic layer was then acidified with conc. HCl to pH 2. The resulting solid was then filtered off, washed with water. The solid was then transferred to a flask and the remaining water was removed by stripping off EtOH (200 mL x 2). The solid was then further dried under high vacuum for 15h to yield 8.75 g (66%) of the title compound as an off-white solid. LRMS ESI⁺ (M+H)⁺ 270.2.

Step 2: 1-tert-butyl 2-methyl (2S,4R)-4-[(6-bromo-7-methoxy-2-oxo-1,2-dihydroquinolin-4-yl)oxy]pyrrolidine-1,2-dicarboxylate

To a solution of 1-tert-butyl 2-methyl (2S,4S)-4-[[[(4-bromophenyl)sulfonyl]oxy]pyrrolidine-1,2-dicarboxylate (4 g, 8.61 mmol) and the product from Step 1, 6-bromo-4-hydroxy-7-methoxyquinolin-2(1H)-one (3.49 g, 12.92 mmol) in NMP (86 ml) under N₂ was added Cs₂CO₃ (8.42 g, 25.8 mmol). The mixture was then heated to 60 °C. After 6.5 h, the reaction was extracted with water and EtOAc. The organic layer was extracted with water and brine and dried over MgSO₄. The solvent was then removed *in vacuo*. The crude product (6.5 g) was purified on silica (gradient elution, 0-100% EtOAc/hex and then 0-5% MeOH/DCM) to yield 2.26 g (53%) of the title compound. LRMS ESI⁺ ((M-Boc)+H)⁺ 397.3.

Step 3: 1-tert-butyl 2-methyl (2S,4R)-4-[(7-methoxy-2-oxo-6-vinyl-1,2-dihydroquinolin-4-yl)oxy]pyrrolidine-1,2-dicarboxylate

To a solution of the product from Step 2, 1-tert-butyl 2-methyl (2S,4R)-4-[(6-bromo-7-methoxy-2-oxo-1,2-dihydroquinolin-4-yl)oxy]pyrrolidine-1,2-dicarboxylate (2.26 g, 4.54 mmol) in EtOH (45.4 mL) was added potassium vinyltrifluoroborate (0.913 g, 6.82 mmol), Et₃N (0.950 mL, 6.82 mmol), and PdCl₂(dppf)-CH₂Cl₂ adduct (0.186 g, 0.227 mmol). The mixture was then heated to reflux for 1 h. The EtOH was removed *in vacuo* and the residue was taken up in EtOAc and extracted with water. The organic layer was dried over MgSO₄ and the solvent was removed *in vacuo*. The crude material was purified on silica gradient elution, 0-5% MeOH/DCM) to yield 2.0 g (99%) of the title compound. LRMS ESI⁺ ((M-Boc)+H)⁺ 345.3.

Step 4: Methyl (4R)-4-[(7-methoxy-2-oxo-6-vinyl-1,2-dihydroquinolin-4-yl)oxy]-L-prolinate hydrochloride

To the product from Step 3, 1-tert-butyl 2-methyl (2S,4R)-4-[(7-methoxy-2-oxo-6-vinyl-1,2-dihydroquinolin-4-yl)oxy]pyrrolidine-1,2-dicarboxylate (2.02 g, 4.54 mmol) was added HCl (4M

in dioxane) (22.72 ml, 91 mmol) at r.t. After 1.5 h, the solvent was removed *in vacuo*. The residue was taken up in Et₂O and the solvent was removed *in vacuo* to yield 1.73 (99%) g of the title compound as a tan solid. LRMS ESI⁺ (M+H)⁺ 345.4.

5 Step 5: Methyl (4R)-1-[(2S)-2-cyclohexyl-2-({[(2,2-dimethylpent-4-en-1-yl)oxy]carbonyl}amino)acetyl]-4-[(7-methoxy-2-oxo-6-vinyl-1,2-dihydroquinolin-4-yl)oxy]-L-prolinate

To a solution of the product from Step 4, methyl (4R)-4-[(7-methoxy-2-oxo-6-vinyl-1,2-dihydroquinolin-4-yl)oxy]-L-prolinate hydrochloride (0.84 g, 2.206 mmol) and linker B20, (2S)-cyclohexyl({[(2,2-dimethylpent-4-en-1-yl)oxy]carbonyl}amino)acetic acid (0.689 g, 2.316 mmol) in DMF (2 mL) was added DIPEA (1.156 mL, 6.62 mmol) and HATU (1.090 g, 2.87 mmol). After 15 min, the reaction was complete and 1 N HCl and EtOAc were added. The organic layer was washed with water and brine, dried over MgSO₄ and the solvent was removed *in vacuo*. The crude product was purified on silica (gradient elution, 0-5% MeOH/DCM) to yield 1.65 g of material which still contained HATU residue. This was removed by extracting the material with EtOAc and 1N HCl (4 x), water (1x) and brine (1x). The organic layer was dried over MgSO₄ and the solvent was removed *in vacuo* to yield 1.13g (82%) of the title compound. LRMS ESI⁺ (M+H)⁺ 624.6.

20 Step 6: Methyl (2R,4S,7S,14E)-7-cyclohexyl-23-methoxy-12,12-dimethyl-6,9,20-trioxo-3,4,6,7,8,9,12,13,19,20-decahydro-2H,11H-16,18-etheno-2,5-methanopyrido[4,3-k][1,10,3,6]dioxadiazacyclononadecine-4-carboxylate

To a degassed (N₂ bubbling for 15 min) solution of the product from Step 5, methyl (4R)-1-[(2S)-2-cyclohexyl-2-({[(2,2-dimethylpent-4-en-1-yl)oxy]carbonyl}amino)acetyl]-4-[(7-methoxy-2-oxo-6-vinyl-1,2-dihydroquinolin-4-yl)oxy]-L-prolinate (1.61 g, 2.58 mmol) in DCM (516 mL) was added the Zhan 1b catalyst (0.189 g, 0.258 mmol). After stirring for 24 h at r.t. and 8h at reflux, conversion was complete. The solvent was removed *in vacuo* and the product was purified on silica (gradient elution, 0-5% MeOH/DCM) to yield 1.53 g (99%) of the title compound as a greenish solid. LRMS ESI⁺ (M+H)⁺ 596.5.

30 Step 7: Methyl (2R,4S,7S)-7-cyclohexyl-23-methoxy-12,12-dimethyl-6,9,20-trioxo-3,4,6,7,8,9,12,13,14,15,19,20-dodecahydro-2H,11H-16,18-etheno-2,5-methanopyrido[4,3-k][1,10,3,6]dioxadiazacyclononadecine-4-carboxylate

To a solution of the product from Step 6, methyl (2R,4S,7S,14E)-7-cyclohexyl-23-methoxy-12,12-dimethyl-6,9,20-trioxo-3,4,6,7,8,9,12,13,19,20-decahydro-2H,11H-16,18-etheno-2,5-methanopyrido[4,3-k][1,10,3,6]dioxadiazacyclononadecine-4-carboxylate (1.53 g, 2.57 mmol) in EtOH (25.7 mL) under N₂ was added Pd/C (0.137 g, 0.128 mmol). The atmosphere was then exchanged for H₂ and the mixture was stirred for 2 days. At this time conversion was <50%, so Pd/C (0.137 g, 0.128 mmol) was added and stirring was continued for 2 days more. The reaction

was then filtered through glass wool and washed with EtOH. The solvent was removed *in vacuo* to yield 1.42 g (92%) of the title compound as a tan solid. ¹H NMR (500 MHz, CDCl₃): δ 9.87 (s, 1H), 7.36 (s, 1H), 6.51 (s, 1H), 5.77 (s, 1H), 5.29 (d, J 9.5, 1H), 5.11 (s, 1H), 4.66 (dd, J 10.25, 7.5, 1H), 4.57 (d, J 12.0, 1H), 4.40 (t, J 10.0, 1H), 4.33 (d, J 11.0, 1H), 3.93 (m, 1H), 3.88 (s, 3H), 3.76 (s, 3H), 3.30 (d, J 10.5, 1H), 2.98 (m, 1H), 2.72 (m, 1H), 2.15 (m, 2H), 1.89 (m, 2H), 1.75 (m, 3H), 1.67 (m, 1H), 1.47-1.03 (m, 8H), 1.01 (s, 3H), 0.83 (m, 1H), 0.78 (s, 3H). LRMS ESI⁺ (M+H)⁺ 598.5.

Step 8: methyl (3R,5S,8S)-8-cyclohexyl-18-methoxy-13,13-dimethyl-7,10-dioxo-22-
10 {[(trifluoromethyl)sulfonyl]oxy}-2,11-dioxo-6,9,21-triazatetracyclo[15.6.2.1^{3,6}.0^{20,24}]hexacosa-
1(24),17,19,20,22,24-hexaene-5-carboxylate

To a solution of the product from Step 7, methyl (2R,4S,7S)-7-cyclohexyl-23-methoxy-12,12-dimethyl-6,9,20-trioxo-3,4,6,7,8,9,12,13,14,15,19,20-dodecahydro-2H,11H-16,18-etheno-2,5-methanopyrido[4,3-*k*][1,10,3,6]dioxadiazacyclononadecine-4-carboxylate (236 mg, 0.395 mmol) in DCM (6 mL) cooled to 0 °C was added pyridine (0.16 mL, 1.97 mmol) and the triflic anhydride (0.1 mL, 0.59 mmol). After 1.5 h, the reaction was diluted with ether and washed with 10 % aqueous NaHCO₃. The organic layer was dried over Na₂SO₄ and the solvent was removed *in vacuo*. The crude product was purified on silica (gradient elution, 20-60% EtOAc/hexanes) to yield the title compound. LRMS ESI⁺ (M+H)⁺ 730.1.

Step 9: methyl (3R,5S,8S)-8-cyclohexyl-18-methoxy-13,13-dimethyl-7,10-dioxo-2,11-dioxo-
20 6,9,21,24-tetraazapentacyclo[15.9.2.1^{3,6}.0^{20,27}.0^{21,25}]nonacosa-1(26),17,19,22,24,27-hexaene-5-
carboxylate

To a mixture of the product from Step 8, methyl (3R,5S,8S)-8-cyclohexyl-18-methoxy-13,13-dimethyl-7,10-dioxo-22-{[(trifluoromethyl)sulfonyl]oxy}-2,11-dioxo-6,9,21-triazatetracyclo[15.6.2.1^{3,6}.0^{20,24}]hexacosa-1(24),17,19,20,22,24-hexaene-5-carboxylate (254 mg, 0.348 mmol) in THF (4 mL) was added 2,2-dimethoxyethanamine (0.75 mL, 6.96 mmol). The mixture was then heated to 100 °C for 18 h. The crude material was then purified by reverse phase chromatography (gradient elution, 0-100% CH₃CN/0.015% TFA in water) to yield the addition product, methyl (3R,5S,8S)-8-cyclohexyl-22-[(2,2-dimethoxyethyl)amino]-18-methoxy-13,13-dimethyl-7,10-dioxo-2,11-dioxo-6,9,21-triazatetracyclo[15.6.2.1^{3,6}.0^{20,24}]hexacosa-1(24),17,19,20,22,24-hexaene-5-carboxylate, which was taken up in xylenes (8 mL) and acetic acid (2.1 mL) and heated to 140 °C overnight. The solvents were then removed *in vacuo* and the crude material was then purified by reverse phase chromatography (gradient elution, 0-100% CH₃CN/0.015% TFA in water) to yield the title compound. LRMS ESI⁺ (M+H)⁺ 621.1.

Step 10: (3R,5S,8S)-8-cyclohexyl-18-methoxy-13,13-dimethyl-7,10-dioxo-2,11-dioxo-6,9,21,24-
tetraazapentacyclo[15.9.2.1^{3,6}.0^{20,27}.0^{21,25}]nonacosa-1(26),17,19,22,24,27-hexaene-5-carboxylic
acid

To a solution of the product from Step 9, methyl (3*R*,5*S*,8*S*)-8-cyclohexyl-18-methoxy-13,13-dimethyl-7,10-dioxo-2,11-dioxa-6,9,21,24-tetraazapentacyclo[15.9.2.1^{3,6}.0^{20,27}.0^{21,25}]nonacosa-1(26),17,19,22,24,27-hexaene-5-carboxylate (100 mg, 0.161 mmol) in THF (4 mL), MeOH (1 mL) and water (1 mL) was added LiOH (39 mg, 1.61 mmol). The mixture was then heated to 50 °C for 1 h and 1N HCl was then added to neutralize the base. The mixture was then extracted with EtOAc, the organic layer was dried over MgSO₄, and the solvent was removed *in vacuo* to yield the title compound. LRMS (M+H)⁺ = 607.1.

Step 11: (3*R*,5*S*,8*S*)-8-cyclohexyl-*N*-((1*R*,2*S*)-1-{[(cyclopropylsulfonyl)amino]carbonyl}-2-vinylcyclopropyl)-18-methoxy-13,13-dimethyl-7,10-dioxo-2,11-dioxa-6,9,21,24-tetraazapentacyclo[15.9.2.1^{3,6}.0^{20,27}.0^{21,25}]nonacosa-1(26),17,19,22,24,27-hexaene-5-carboxamide

To a solution of the product from Step 10, (3*R*,5*S*,8*S*)-8-cyclohexyl-18-methoxy-13,13-dimethyl-7,10-dioxo-2,11-dioxa-6,9,21,24-tetraazapentacyclo[15.9.2.1^{3,6}.0^{20,27}.0^{21,25}]nonacosa-1(26),17,19,22,24,27-hexaene-5-carboxylic acid (75 mg, 0.124 mmol) in DMF (1 mL) was added acylsulfonamide intermediate A1 (40 mg, 0.15 mmol), DIPEA (0.065 mL, 0.37 mmol), HATU (56 mg, 0.15 mmol), and DMAP (7.5 mg, 0.062 mmol). After 30 min, the mixture was purified directly by reverse phase chromatography (100x30 mm, 0-100% ACN/0.15% aqueous TFA) to give the title compound as a white solid. LRMS (M+H)⁺ = 819.2.

Example 39: (3*R*,5*S*,8*S*)-8-cyclohexyl-*N*-((1*R*,2*R*)-1-{[(cyclopropylsulfonyl)amino]carbonyl}-2-ethylcyclopropyl)-18-methoxy-13,13-dimethyl-7,10-dioxo-2,11-dioxa-6,9,21,24-tetraazapentacyclo[15.9.2.1^{3,6}.0^{20,27}.0^{21,25}]nonacosa-1(26),17,19,22,24,27-hexaene-5-carboxamide

The title compound was prepared according to the procedure in Example 38 except intermediate A3 was used in place of intermediate A1 in Step 11. LRMS (M+H)⁺ = 821.2.

Example 40: (3*R*,5*S*,8*S*)-8-cyclohexyl-*N*-((1*R*,2*S*)-1-{[(cyclopropylsulfonyl)amino]carbonyl}-2-vinylcyclopropyl)-13,13-dimethyl-7,10-dioxo-2,11-dioxa-6,9,21,24-tetraazapentacyclo[15.9.2.1^{3,6}.0^{20,27}.0^{21,25}]nonacosa-1(26),17,19,22,24,27-hexaene-5-carboxamide

The title compound was prepared according to the procedure for Example 38, except 4-bromoaniline was used in place of 4-bromo-3-methoxyaniline in Step 1. LRMS (M+H)⁺ = 789.2.

Example 41: (3*R*,5*S*,8*S*)-8-cyclohexyl-*N*-((1*R*,2*S*)-1-{[(cyclopropylsulfonyl)amino]carbonyl}-2-vinylcyclopropyl)-13,13-dimethyl-7,10-dioxo-2,11-dioxa-6,9,22,23,25,26-hexaazapentacyclo[15.9.2.1^{3,6}.0^{20,27}.0^{21,25}]nonacosa-1(26),17,19,21,23,27-hexaene-5-carboxamide

Step 1: 6-bromo-2,3-dihydrophthalazine-1,4-dione

Hydrazine monohydrate (2 ml, 33.0 mmol) was added to a suspension of 4-bromophthalic anhydride (7.5 g, 33.0 mmol) in ethanol (70 ml) and the resulting mixture was stirred at 90°C for 24 hr. The volume of the reaction mixture was then reduced to half volume under reduced pressure and the residue was treated 0.5 N aq. HCl (20 mL). The title compound precipitated as a white solid and was collected by filtration (4.86g, 61%); LRMS ESI⁺ (M+H)⁺ 241.

Step 2: 6-bromo-1,4-dichlorophthalazine

A solution of 6-bromo-2,3-dihydrophthalazine-1,4-dione from Step 1 (4.86 g, 20.16 mmol) in POCl₃ (100 ml) was heated at 120°C for 16hr. POCl₃ was then removed under reduced pressure and the residue was dissolved in DCM and cold water. Solid NaHCO₃ was carefully added till pH = 11 was reached, the aq. layer was separated and further extracted with DCM. The combined organic layers were washed with brine, dried (Na₂SO₄) and concentrated under reduced pressure to give the title compound as a pale yellow solid (4.13 g, 73%); LRMS ESI⁺ (M+H)⁺ 279.

Step 3: 8-bromo-6-chloro[1,2,4]triazolo[3,4-a]phthalazine and 9-bromo-6-chloro[1,2,4]triazolo[3,4-a]phthalazine

To a solution of 6-bromo-1,4-dichlorophthalazine from Step 2 (400 mg, 1.44 mmol) in xylene (5 ml) was added Et₃N (0.24 ml, 1.7 mmol) and formic acid hydrazide (95 mg, 1.58 mmol). The resulting mixture was heated at reflux for 16 hr and the volatiles were then removed under reduced pressure. The solid residue was partitioned between DCM and water. The organic layer was dried over Na₂SO₄, filtered, concentrated under reduced pressure and the residue was purified by SiO₂ gel chromatography (eluent: DCM to DCM/MeOH 3%) to give the title compound as a yellow solid mixture of regioisomers (196 mg, 48%); LRMS ESI⁺ (M+H)⁺ 284.

Step 4: 1-tert-butyl 2-methyl (2S,4R)-4-[(8-bromo[1,2,4]triazolo[3,4-a]phthalazin-6-yl)oxy]pyrrolidine-1,2-dicarboxylate and 1-tert-butyl 2-methyl (2S,4R)-4-[(9-bromo[1,2,4]triazolo[3,4-a]phthalazin-6-yl)oxy]pyrrolidine-1,2-dicarboxylate

To a solution of 1-tert-butyl 2-methyl (2S,4R)-4-hydroxypyrrolidine-1,2-dicarboxylate (170 mg, 0.69 mmol) in DMF (2 ml) at -10 °C was added dropwise a 1M solution of lithium bis(trimethylsilyl)amide (0.75 ml, 0.75 mmol) in THF. The resulting mixture was stirred at -10 °C for 1 hr before adding the product from Step 3 (196 mg, 0.69 mmol) in one portion. The mixture was then stirred at rt for 16 hrs, cooled to 0 °C, water was added (0.4 mL) and all the volatiles were removed under reduced pressure. The residue was purified by SiO₂ gel chromatography (eluent: DCM to DCM/MeOH 3%) to give title compound as a mixture of regioisomers (247 mg, 73%); LRMS ESI⁺ (M+H)⁺ 493.

Step 5: 1-tert-butyl 2-methyl (2S,4R)-4-[(8-vinyl[1,2,4]triazolo[3,4-a]phthalazin-6-yl)oxy]pyrrolidine-1,2-dicarboxylate and 1-tert-butyl 2-methyl (2S,4R)-4-[(9-vinyl[1,2,4]triazolo[3,4-a]phthalazin-6-yl)oxy]pyrrolidine-1,2-dicarboxylate

To a solution of the product from Step 4 (207 mg, 0.42 mmol) in EtOH (5 mL) was added potassium vinyl-trifluoroborate (65 mg, 0.46 mmol), triethylamine (0.09 ml, 0.63 mmol) and PdCl₂(dppf)-CH₂Cl₂ adduct (17 mg, 0.02 mmol) and the resulting mixture was heated at 90 °C for 1 hr. The volatiles were then removed under reduced pressure, and the residue was purified by SiO₂ gel chromatography (eluent: DCM to DCM/MeOH = 98/2) to give the title product as mixture of regioisomers (177 mg, 95%); LRMS ESI⁺ (M+H)⁺ 440.

Step 6: Methyl (2S,4R)-4-[(8-vinyl[1,2,4]triazolo[3,4-a]phthalazin-6-yl)oxy]pyrrolidine-2-dicarboxylate hydrochloride and methyl (2S,4R)-4-[(9-vinyl[1,2,4]triazolo[3,4-a]phthalazin-6-yl)oxy]pyrrolidine-2-dicarboxylate hydrochloride

To a solution of the product from Step 5 (177 mg, 0.20 mmol) in 4N HCl / dioxane was stirred at rt for 1 hr. The volatiles were then removed under reduced pressure and the resulting residue was used without further purification in the following step; LRMS ESI⁺ (M+H)⁺ 340.

Step 7: Methyl (2S,4R)-1-[(2)-2-cyclohexyl-2-({[(2,2-dimethylpent-4-en-1-yl)oxy]carbonyl}amino)acetyl]-4-[(8-vinyl[1,2,4]triazolo[3,4-a]phthalazin-6-yl)oxy]pyrrolidine-2-carboxylate and methyl (2S,4R)-1-[(2)-2-cyclohexyl-2-({[(2,2-dimethylpent-4-en-1-yl)oxy]carbonyl}amino)acetyl]-4-[(9-vinyl[1,2,4]triazolo[3,4-a]phthalazin-6-yl)oxy]pyrrolidine-2-carboxylate

To a solution of product from Step 6 (145 mg, 0.19 mmol) in DMF (5 mL) was added intermediate B20 (57.4 mg, 0.19 mmol), DIPEA (0.12 ml, 0.67 mmol) and TBTU (68 mg, 0.21 mmol). The resulting reaction mixture was stirred at rt for 16 hr, diluted with EtOAc and washed with 1N aq HCl, ss NaHCO₃ and brine. The organic phase was dried (Na₂SO₄), concentrated under reduced pressure and purified by SiO₂ gel chromatography (eluent: DCM\MeOH 1% to 3%) to give the title compound as a pale orange foam (200 mg, 83%); LRMS ESI⁺ (M+H)⁺ 619.

Step 8: methyl (3R,5S,8S,15E)-8-cyclohexyl-13,13-dimethyl-7,10-dioxo-2,11-dioxa-6,9,22, 23, 25,26-hexaazapentacyclo[15.9.2.1^{3,5}.0^{20,27}.0^{21,25}]nonacosa-1(26),15,17,19,21,23,27-heptaene-5-carboxylate

The title compound was prepared from the product obtained in Step 7 (150 mg, 0.12 mmol) as described for Example 1, Step 6. SiO₂ gel chromatography (eluent: DCM\MeOH 1% to 3%) gave the title compound as a glass (70 mg, 98%); LRMS ESI⁺ (M+H)⁺ 591.

Step 9 : methyl (3R,5S,8S)-8-cyclohexyl-13,13-dimethyl-7,10-dioxo-2,11-dioxa-6,9,22, 23, 25,26-hexaazapentacyclo[15.9.2.1^{3,5}.0^{20,27}.0^{21,25}]nonacosa-1(26),17,19,21,23,27-hexaene-5-carboxylate

To a solution of product from Step 8 (70 mg, 0.12 mmol) in MeOH (2 mL) was added 10% Pd/C (13 mg) and the resulting mixture was stirred at rt under hydrogen atmosphere for 16 hr. The catalyst was removed by filtration and the volatiles were removed under reduced pressure.

The title compound was used without further purification in the following step; LRMS ESI⁺ (M+H)⁺ 592.

Step 10: (3*R*,5*S*,8*S*)-8-cyclohexyl-13,13-dimethyl-7,10-dioxo-2,11-dioxo-6,9,22, 23, 25,26-hexaazapentacyclo[15.9.2.1^{3,5}.0^{20,27}.0^{21,25}]nonacosa-1(26),17,19,21,23,27-hexaene-5-carboxylic acid

To a solution of the product from Step 9 (70 mg, 0.12 mmol) in THF/H₂O 1/1 v/v (5 mL) was added LiOH (23 mg, 0.95 mmol) and the resulting mixture was stirred at rt for 1 hr. The reaction mixture was then brought to pH =2 by addition of 0.16 mL of 6N aq. HCl and the volatiles were removed under reduced pressure to give the title compound which was used without further purification in the following step; LRMS ESI⁺ (M+H)⁺ 579.

Step 11: (3*R*,5*S*,8*S*)-8-cyclohexyl-*N*-((1*R*,2*S*)-1-{[(cyclopropylsulfonyl)amino]carbonyl}-2-vinylcyclopropyl)- 13,13-dimethyl-7,10-dioxo-2,11-dioxo-6,9,22, 23, 25,26-hexaazapentacyclo[15.9.2.1^{3,6}.0^{20,27}.0^{21,25}]nonacosa-1(26),17,19,21,23,27-hexaene-5-carboxamide

To a solution of the product from Step 10 (0.12 mmol) in DMF (3 mL) were added intermediate A1 (32 mg, 0.12), DIPEA (54 mg, 0.07 mmol) and TBTU (42 mg, 0.13 mmol). The resulting reaction mixture was stirred at rt 16 hr and purified directly by reverse phase chromatography (100x30 mm, 40-95% ACN/0.15% aq. TFA) to give the title compound as a white solid product (13 mg; 14%); LRMS ESI⁺ (M+H)⁺ 791.1; ¹H NMR (400 MHz, DMSO-d₆): δ 10.45 (s, 1H), 9.38 (s, 1H), 8.87 (s, 1H), 8.37 (d, J 7.9, 1H), 8.16 (s, 1H), 7.89 (d, J 7.9, 1H), 7.79 (s, 1H), 7.67 (d, J 7.7, 1H), 5.77 (s, 1H), 5.59 (m, 1H), 5.22 (d, J 16.4, 1H), 5.10 (d, J 11.4, 1H), 4.59 (d, J 9.6, 1H), 4.31 (m, 1H), 4.23 (d, J 10.7, 1H), 4.15 (m, 1H), 3.99 (d, J 11.8, 1H), 3.26 (m, 1H), 2.94 (m, 1H), 2.86 (m, 1H), 2.68 (m, 1H), 2.59 (m, 1H), 2.19 (m, 1H), 1.92 (s, 2H), 1.84 (m, 1H), 1.74-1.50 (m, 5H), 1.41 (m, 1H), 1.25-0.83 (m, 15H), 0.76 (s, 3H).


Example 42: (3*R*,5*S*,8*S*,15*E*)-8-cyclohexyl-*N*-((1*R*,2*S*)-1-{[(cyclopropylsulfonyl)amino]carbonyl}-2-vinylcyclopropyl)- 13,13-dimethyl-7,10-dioxo-2,11-dioxo-6,9,22, 23, 25,26-hexaazapentacyclo[15.9.2.1^{3,5}.0^{20,27}.0^{21,25}]nonacosa-1(26),15,17,19,21,23,27-heptaene-5-carboxamide

The title compound was prepared as described for Example 41, employing methyl (3*R*,5*S*,8*S*,15*E*)-8-cyclohexyl-13,13-dimethyl-7,10-dioxo-2,11-dioxo-6,9,22, 23, 25,26-hexaazapentacyclo[15.9.2.1^{3,5}.0^{20,27}.0^{21,25}]nonacosa-1(26),15,17,19,21,23,27-heptaene-5-carboxylate instead of (3*R*,5*S*,8*S*)-8-cyclohexyl-13,13-dimethyl-7,10-dioxo-2,11-dioxo-6,9,22, 23, 25,26-hexaazapentacyclo[15.9.2.1^{3,5}.0^{20,27}.0^{21,25}]nonacosa-1(26),17,19,21,23,27-hexaene-5-carboxylic acid in Step 10; white solid; LRMS ESI⁺ (M+H)⁺ 789.2; ; ¹H NMR (600 MHz, DMSO-d₆): δ 10.40 (s, 1H), 9.38 (s, 1H), 8.80 (s, 1H), 8.37 (d, J 8.1, 1H), 8.33 (s, 1H), 8.12 (s, 1H), 7.88-7.86 (m, 2H), 6.60 (d, J 16.0, 1H), 6.45 (m, 1H), 5.63 (s, 1H), 5.53 (m, 1H), 5.16 (d, J

15.9, 1H), 5.05 (d, J 11.4, 1H), 4.77 (d, J 11.5, 1H), 4.36 (d, J 11.7, 1H), 4.21 (m, 1H), 3.95 (d, J 10.4, 1H), 3.25 (m, 1H), 2.92 (m, 1H), 2.78 (m, 1H), 2.28 (m, 1H), 2.12 (m, 1H), 2.03-2.00 (m, 2H), 1.94 (m, 1H), 1.80 (m, 1H), 1.70-1.61 (m, 3H), 1.23-0.92 (m, 15H), 0.82 (s, 3H).

Claims

1. A compound of formula (I):



5 or a pharmaceutically acceptable salt thereof,
wherein:

m is 0, 1, 2 or 3;

n is 0, 1 or 2;

R^1 is CO_2R^5 , $\text{CONR}^5\text{SO}_2R^5$, $\text{CONR}^5\text{SO}_2\text{N}(R^5)_2$ or tetrazolyl;

10 R^a is C_{2-6} alkylene- R^2 ;

R^b is hydrogen;

or R^a and R^b , together with the carbon atom to which they are attached, form a C_{3-6} cycloalkyl group, optionally substituted by R^2 ;

15 R^2 is C_{1-6} alkyl, C_{2-6} alkenyl or C_{3-8} cycloalkyl, wherein said alkyl, alkenyl or cycloalkyl is optionally substituted with 1 to 3 halo;

R^3 is C_{1-6} alkyl, $(\text{CH}_2)_{0-3}\text{C}_{3-8}$ cycloalkyl, $(\text{CH}_2)_{0-3}$ aryl or $(\text{CH}_2)_{0-3}$ Het, optionally substituted by halo, OR^5 , SR^5 , $\text{N}(R^5)_2$, C_{1-6} alkyl, NO_2 , CN , CF_3 , $\text{NR}^5\text{SO}_2R^5$, $\text{SO}_2\text{N}(R^5)_2$, NHCO_2R^5 , NHCOR^5 , NHCONHR^5 , CO_2R^5 , C(O)R^5 or $\text{CON}(R^5)_2$;

each R^5 is independently hydrogen, C_{1-6} alkyl or C_{3-8} cycloalkyl;

20 each W is independently halo, OR^5 , C_{1-6} alkyl, CN , NO_2 , CF_3 , CO_2R^5 , $\text{CON}(R^5)_2$, COR^5 , $\text{NR}^5\text{C(O)R}^5$, aryl or heteroaryl;

Z is O or NR^6 ;

R^6 is hydrogen or C_{1-6} alkyl;

Y is C=O , SO_2 or CR^cR^d ;

25 X is O, NR^e or CR^eR^f ;

R^c , R^d , R^e and R^f are independently hydrogen, halo or C_{1-6} alkyl;

M is C_{4-12} alkylene, C_{4-12} alkenylene or C_{4-12} alkynylene, optionally substituted by C_{1-6} alkyl, $(\text{CH}_2)_{0-3}\text{C}_{3-8}$ cycloalkyl, $(\text{CH}_2)_{0-3}$ aryl, and optionally containing one O or S atom or one NH or NC_{1-6} alkyl group, and optionally spiro-fused to a C_{3-7} cycloalkyl group, and optionally fused to a

3- to 8-membered ring, which ring optionally contains 1 or 2 heteroatoms selected from N, O and S;

ring A is a 8- to 10-membered fused heterobicyclic ring system containing 1 to 4 heteroatoms selected from N, O and S, where one and only one of the rings of the heterobicyclic ring system is fused to a 5- or 6-membered ring, which ring may optionally contain 1 or 2 heteroatoms selected from N, O and S; and

R^4 is halo, hydroxy, C_{1-6} alkyl, C_{1-6} alkoxy, CN, NO_2 , oxo, C_{3-8} cycloalkyl, $N(R^5)_2$, aryl or heteroaryl, optionally substituted by 1 to 8 halo or C_{1-4} alkyl.

2. A compound as claimed in Claim 1 wherein m or n is independently 0 or 1.

3. A compound as claimed in Claim 1 or 2 wherein R^1 is $CONR^5SO_2R^5$ or $CONR^5SO_2N(R^5)_2$ where R^5 is as defined in Claim 1.

4. A compound as claimed in any one of Claims 1 to 3 wherein R^a is C_{2-5} alkylene- R^2 where R^2 is as defined in Claim 1, R^b is hydrogen or R^a and R^b , together with the carbon atom to which they are attached, form a C_{3-5} cycloalkyl group, optionally substituted by R^2 , where R^2 is C_{1-6} alkyl or C_{2-6} alkenyl.

5. A compound as claimed in any one of Claims 1 to 4 wherein R^3 is C_{1-6} alkyl, or $(CH_2)_{0-3}C_{3-8}$ cycloalkyl, optionally substituted by halo, OR^5 or C_{1-6} alkyl, where R^5 is as defined in Claim 1.

6. A compound as claimed in any one of Claims 1 to 5 wherein each W is independently halo, OR^5 , C_{1-6} alkyl, CN, NO_2 , CF_3 , CO_2R^5 or $CON(R^5)_2$, where R^5 is as defined in Claim 1.



7. A compound as claimed in any one of Claims 1 to 6 wherein Z is O, Y is C=O and X is O or NR^c , where R^c is as defined in Claim 1.

8. A compound as claimed in any one of Claims 1 to 7 wherein M is C_{4-10} alkylene, C_{4-10} alkenylene or C_{4-10} alkynylene, optionally substituted by C_{1-6} alkyl or $(CH_2)_{0-3}C_{3-8}$ cycloalkyl, and optionally containing one O or S group or one NH or NC_{1-4} alkyl group, and optionally fused to a 3- to 8- membered carbocyclic ring.


9. A compound as claimed in any one of Claims 1 to 8 wherein A is a 9- or 10-membered fused heterobicyclic ring system containing 1 to 3 heteroatoms selected from N and O, where one and only one of the rings of the heterobicyclic system is fused to a 5- or 6-membered ring, which ring may optionally contain 1 or 2 heteroatoms selected from N and S, and which ring is optionally substituted by R^4 , where R^4 is as defined in Claim 1.

10. A compound as claimed in any one of Claims 1 to 9 wherein R^4 is halo, hydroxy, C_{1-6} alkyl, C_{1-6} alkoxy, CN, C_{3-8} cycloalkyl or aryl.


5 11. A compound as claimed in Claim 1 according to any one of formulas (Ia), (Iaa), (Iab), (Iad) and (Iae):




- 58 -



(lab)



(lad)



(lae)

or a pharmaceutically acceptable salt thereof, wherein R^1 , R^2 , R^3 , R^4 , W, n, X, Y, Z and M are as defined in Claim 1;

D^1 is C and D^2 is N and the dotted line represents a double bond;



or D^1 is N and D^2 is CH and the dotted line represents a single bond;

5 ring C is a 5- or 6-membered ring optionally containing 1 or 2 heteroatoms selected from N and S; and

ring D is a 5- or 6-membered ring optionally containing one or two N atoms.

12. A compound as claimed in Claim 1 according to formulas (Ib) and (Iba):

10



or a pharmaceutically acceptable salt thereof, wherein R^1 , R^2 , R^3 , R^4 , W, X, Y, Z and M are as defined in Claim 1;

15 one of D^1 and D^2 is CH and the other of D^1 and D^2 is N; and

ring C is a 5- or 6-membered ring optionally containing 1 or 2 heteroatoms selected from N and S.

13. A compound as claimed in Claim 1 which is selected from:

(2*R*,4*S*,7*S*)-7-cyclohexyl-*N*-((1*R*,2*S*)-1-{[(cyclopropylsulfonyl)amino]carbonyl}-2-vinylcyclopropyl)-12,12-dimethyl-6,9-dioxo-3,4,6,7,8,9,12,13,14,15-decahydro-2*H*,11*H*-16,18-(ethanediylidene)-2,5-methano[1,10,3,6]dioxadiazacyclononadecino[11,12-*b*]quinoline-4-carboxamide,

(2*R*,4*S*,7*S*,14*E*)-21-cyano-7-cyclopentyl-*N*-((1*R*,2*S*)-1-{[(cyclopropylsulfonyl)amino]carbonyl}-2-vinylcyclopropyl)-25-methoxy-12,12-dimethyl-6,9-dioxo-3,4,6,7,8,9,12,13-octahydro-2*H*,11*H*-16,18-(ethanediylidene)-2,5-methano[1,10,3,6]dioxadiazacyclononadecino[11,12-*b*]quinoline-4-carboxamide,

(2*R*,4*S*,7*S*)-21-cyano-7-cyclopentyl-*N*-((1*R*,2*S*)-1-{[(cyclopropylsulfonyl)amino]carbonyl}-2-vinylcyclopropyl)-25-methoxy-12,12-dimethyl-6,9-dioxo-3,4,6,7,8,9,12,13,14,15-decahydro-2*H*,11*H*-16,18-(ethanediylidene)-2,5-methano[1,10,3,6]dioxadiazacyclononadecino[11,12-*b*]quinoline-4-carboxamide,

(3*R*,5*S*,8*S*)-8-cyclohexyl-*N*-((1*R*,2*S*)-1-{[(cyclopropylsulfonyl)amino]carbonyl}-2-vinylcyclopropyl)-18-methoxy-13,13-dimethyl-7,10-dioxo-2,11-dioxa-6,9,27-triazapentacyclo[15.10.2.1^{3,6}.0^{20,28}.0^{21,26}]triaconta-1(27),15,17,19,21(26),28-hexaene-5-carboxamide,

(3*R*,5*S*,8*S*)-8-cyclohexyl-*N*-((1*R*,2*S*)-1-{[(cyclopropylsulfonyl)amino]carbonyl}-2-vinylcyclopropyl)-18-methoxy-13,13-dimethyl-7,10-dioxo-2,11-dioxa-6,9,27-triazapentacyclo[15.10.2.1^{3,6}.0^{20,28}.0^{21,26}]triaconta-1(27),17,19,21(26),28-pentaene-5-carboxamide,

(2*R*,4*S*,7*S*)-7-cyclopentyl-*N*-((1*R*,2*S*)-1-{[(cyclopropylsulfonyl)amino]carbonyl}-2-vinylcyclopropyl)-25-methoxy-12,12-dimethyl-6,9-dioxo-3,4,6,7,8,9,12,13,14,15-decahydro-2*H*,11*H*-16,18-(ethanediylidene)-2,5-methano[1,10,3,6]dioxadiazacyclononadecino[11,12-*b*]quinoline-4-carboxamide,

(2*R*,4*S*,7*S*)-7-cyclopentyl-*N*-((1*R*,2*S*)-1-{[(cyclopropylsulfonyl)amino]carbonyl}-2-vinylcyclopropyl)-25-methoxy-12,12,21-trimethyl-6,9-dioxo-3,4,6,7,8,9,12,13,14,15-decahydro-2*H*,11*H*-16,18-etheno-2,5-methano[1,10,3,6]dioxadiazacyclononadecino[11,12-*b*]quinoline-4-carboxamide,

(2*R*,4*S*,7*S*,14*E*)-7-cyclohexyl-*N*-((1*R*,2*S*)-1-{[(cyclopropylsulfonyl)amino]carbonyl}-2-vinylcyclopropyl)-25-methoxy-10,12,12-trimethyl-6,9-dioxo-3,4,6,7,8,9,10,11,12,13-decahydro-2*H*-16,18-etheno-2,5-methano[1,5,8,10]oxatriazacyclononadecino[19,18-*b*]quinoline-4-carboxamide,

(2*R*,4*S*,7*S*,14*Z*)-7-cyclohexyl-*N*-((1*R*,2*S*)-1-{[(cyclopropylsulfonyl)amino]carbonyl}-2-vinylcyclopropyl)-25-methoxy-10,12,12-trimethyl-6,9-dioxo-3,4,6,7,8,9,10,11,12,13-decahydro-2*H*-16,18-etheno-2,5-methano[1,5,8,10]oxatriazacyclononadecino[19,18-*b*]quinoline-4-carboxamide,

(2*R*,4*S*,7*S*)-7-cyclohexyl-*N*-((1*R*,2*S*)-1-{[(cyclopropylsulfonyl)amino]carbonyl}-2-vinylcyclopropyl)-25-methoxy-10,12,12-trimethyl-6,9-dioxo-3,4,6,7,8,9,10,11,12,13,14,15-dodecahydro-2*H*-16,18-etheno-2,5-methano[1,5,8,10]oxatriazacyclononadecino[19,18-*b*]quinoline-4-carboxamide,

(3*aR*,7*S*,10*S*,12*R*,24*aR*)-7-cyclohexyl-*N*-((1*R*,2*S*)-1-{[(cyclopropylsulfonyl)amino]carbonyl}-2-vinylcyclopropyl)-25-methoxy-5,8-dioxo-1,2,3,3*a*,5,6,7,8,11,12,22,23,24,24*a*-tetradecahydro-10*H*-19,21-etheno-9,12-methanocyclopenta[18,19][1,10,3,6]dioxadiazacyclononadecino[11,12-*b*]quinoline-10-carboxamide,

(3*aS*,7*S*,10*S*,12*R*,24*aS*)-7-cyclohexyl-*N*-((1*R*,2*S*)-1-{[(cyclopropylsulfonyl)amino]carbonyl}-2-vinylcyclopropyl)-25-methoxy-5,8-dioxo-1,2,3,3*a*,5,6,7,8,11,12,22,23,24,24*a*-tetradecahydro-10*H*-19,21-etheno-9,12-methanocyclopenta[18,19][1,10,3,6]dioxadiazacyclononadecino[11,12-*b*]quinoline-10-carboxamide,

(2*R*,4*S*,7*S*,14*E*)-20-chloro-7-cyclopentyl-*N*-((1*R*,2*S*)-1-{[(cyclopropylsulfonyl)amino]carbonyl}-2-vinylcyclopropyl)-25-methoxy-12,12-dimethyl-6,9-dioxo-3,4,6,7,8,9,12,13-octahydro-2*H*,11*H*-16,18-etheno-2,5-methano[1,10,3,6]dioxadiazacyclononadecino[11,12-*b*]quinoline-4-carboxamide,

(2*R*,4*S*,7*S*)-20-chloro-7-cyclopentyl-*N*-((1*R*,2*S*)-1-{[(cyclopropylsulfonyl)amino]carbonyl}-2-vinylcyclopropyl)-25-methoxy-12,12-dimethyl-6,9-dioxo-3,4,6,7,8,9,12,13,14,15-decahydro-2*H*,11*H*-16,18-etheno-2,5-methano[1,10,3,6]dioxadiazacyclononadecino[11,12-*b*]quinoline-4-carboxamide,

(2*R*,4*S*,7*S*)-7-cyclopentyl-*N*-((1*R*,2*S*)-1-{[(cyclopropylsulfonyl)amino]carbonyl}-2-vinylcyclopropyl)-21-fluoro-25-methoxy-12,12-dimethyl-6,9-dioxo-3,4,6,7,8,9,12,13,14,15-decahydro-2*H*,11*H*-16,18-(ethanediylidene)-2,5-methano[1,10,3,6]dioxadiazacyclononadecino[11,12-*b*]quinoline-4-carboxamide,

(2*R*,4*S*,7*S*,14*E*)-7-cyclopentyl-*N*-((1*R*,2*S*)-1-{[(cyclopropylsulfonyl)amino]carbonyl}-2-vinylcyclopropyl)-21,25-dimethoxy-12,12-dimethyl-6,9-dioxo-3,4,6,7,8,9,12,13-octahydro-2*H*,11*H*-16,18-(ethanediylidene)-2,5-methano[1,10,3,6]dioxadiazacyclononadecino[11,12-*b*]quinoline-4-carboxamide,

(2*R*,4*S*,7*S*)-7-cyclopentyl-*N*-((1*R*,2*S*)-1-{[(cyclopropylsulfonyl)amino]carbonyl}-2-vinylcyclopropyl)-21,25-dimethoxy-12,12-dimethyl-6,9-dioxo-3,4,6,7,8,9,12,13,14,15-decahydro-2*H*,11*H*-16,18-(ethanediylidene)-2,5-methano[1,10,3,6]dioxadiazacyclononadecino[11,12-*b*]quinoline-4-carboxamide,

(3*R*,5*S*,8*S*)-8-cyclopentyl-*N*-((1*R*,2*S*)-1-{[(cyclopropylsulfonyl)amino]carbonyl}-2-vinylcyclopropyl)-26-ethoxy-13,13-dimethyl-7,10-dioxo-2,11-dioxo-6,9,25-triazapentacyclo[15.10.2.1^{3,6}.0^{18,23}.0^{24,28}]triaconta-1(27),15,17,19,21,23,25,28-octaene-5-carboxamide,

(3*R*,5*S*,8*S*)-8-*tert*-butyl-*N*-((1*R*,2*S*)-1-{[(cyclopropylsulfonyl)amino]carbonyl}-2-vinylcyclopropyl)-18-methoxy-13,13-dimethyl-7,10-dioxo-2,11-dioxo-6,9,27-

triazapentacyclo[15.10.2.1^{3,6}.0^{20,28}.0^{21,26}]triaconta-1(27),15,17,19,21(26),28-hexaene-5-carboxamide,

(3*R*,5*S*,8*S*)-8-cyclohexyl-*N*-((1*R*,2*R*)-1-{[(cyclopropylsulfonyl)amino]carbonyl}-2-ethylcyclopropyl)-18-methoxy-13,13-dimethyl-7,10-dioxo-2,11-dioxo-6,9,27-

triazapentacyclo[15.10.2.1^{3,6}.0^{20,28}.0^{21,26}]triaconta-1(27),17,19,21(26),28-pentaene-5-carboxamide,

(3*R*,5*S*,8*S*)-8-cyclohexyl-*N*-((1*R*,2*R*)-1-{[(cyclopropylsulfonyl)amino]carbonyl}-2-ethylcyclopropyl)-18-methoxy-13,13-dimethyl-7,10-dioxo-2,11-dioxo-6,9,27-

triazapentacyclo[15.10.2.1^{3,6}.0^{20,28}.0^{21,26}]triaconta-1(27),15,17,19,21(26),28-hexaene-5-carboxamide,

(3*R*,5*S*,8*S*)-8-cyclohexyl-*N*-((1*R*,2*S*)-1-{[(cyclopropylsulfonyl)amino]carbonyl}-2-vinylcyclopropyl)-18-methoxy-13,13-dimethyl-7,10-dioxo-2,11-dioxo-6,9,26-

triazapentacyclo[15.9.2.1^{3,6}.0^{20,27}.0^{21,25}]nonacosa-1(26),17,19,21(25),27-pentaene-5-carboxamide,

(2*R*,4*S*,7*S*,14*E*)-7-cyclohexyl-*N*-((1*R*,2*S*)-1-{[(cyclopropylsulfonyl)amino]carbonyl}-2-

vinylcyclopropyl)-24-methoxy-12,12-dimethyl-6,9-dioxo-3,4,6,7,8,9,12,13-octahydro-2*H*,11*H*-16,18-etheno-2,5-methanothieno[3',2':5,6]pyrido[2,3-*k*][1,10,3,6]dioxadiazacyclononadecine-4-carboxamide,

(2*R*,4*S*,7*S*)-7-cyclohexyl-*N*-((1*R*,2*S*)-1-{[(cyclopropylsulfonyl)amino]carbonyl}-2-

vinylcyclopropyl)-24-methoxy-12,12-dimethyl-6,9-dioxo-3,4,6,7,8,9,12,13,14,15-decahydro-2*H*,11*H*-16,18-etheno-2,5-methanothieno[3',2':5,6]pyrido[2,3-

k][1,10,3,6]dioxadiazacyclononadecine-4-carboxamide,

(2*R*,4*S*,7*S*,14*E*)-7-butyl-*N*-((1*R*,2*S*)-1-{[(cyclopropylsulfonyl)amino]carbonyl}-2-

vinylcyclopropyl)-24-methoxy-12,12-dimethyl-6,9-dioxo-3,4,6,7,8,9,12,13-octahydro-2*H*,11*H*-16,18-(ethanediylidene)-2,5-methanothieno[3',2':5,6]pyrido[2,3-

k][1,10,3,6]dioxadiazacyclononadecine-4-carboxamide,

(2*R*,4*S*,7*S*,14*E*)-7-cyclopentyl-*N*-((1*R*,2*S*)-1-{[(cyclopropylsulfonyl)amino]carbonyl}-2-

vinylcyclopropyl)-24-methoxy-12,12-dimethyl-6,9-dioxo-3,4,6,7,8,9,12,13-octahydro-2*H*,11*H*-16,18-(ethanediylidene)-2,5-methanothieno[3',2':5,6]pyrido[2,3-

k][1,10,3,6]dioxadiazacyclononadecine-4-carboxamide,

(2*R*,4*S*,7*S*,14*E*)-7-*tert*-butyl-*N*-((1*R*,2*S*)-1-{[(cyclopropylsulfonyl)amino]carbonyl}-2-

vinylcyclopropyl)-24-methoxy-12,12-dimethyl-6,9-dioxo-3,4,6,7,8,9,12,13-octahydro-2*H*,11*H*-16,18-(ethanediylidene)-2,5-methanothieno[3',2':5,6]pyrido[2,3-*k*][1,10,3,6]dioxadiazacyclo

nonadecine-4-carboxamide,

(4*E*,13*S*,16*S*,18*R*)-13-*tert*-butyl-*N*-((1*R*,2*S*)-1-{[(cyclopropylsulfonyl)amino]carbonyl}-2-

vinylcyclopropyl)-1,8,8-trimethyl-11,14-dioxo-6,7,8,9,11,12,13,14,17,18-decahydro-3*H*,16*H*-15,18-methano-10,19-dioxo-2*a*,12,15,20-tetraazabenzog[c]cycloicosa[1,2,3-*cd*]indene-16-

carboxamide,

(13*S*,16*S*,18*R*)-13-*tert*-butyl-*N*-((1*R*,2*S*)-1-{[(cyclopropylsulfonyl)amino]carbonyl}-2-vinylcyclopropyl)-1,8,8-trimethyl-11,14-dioxo-4,5,6,7,8,9,11,12,13,14,17,18-dodecahydro-3*H*,16*H*-15,18-methano-10,19-dioxo-2a,12,15,20-tetraazabenz[*g*]cycloicosa[1,2,3-*cd*]indene-16-carboxamide,

(4*E*,12*S*,15*S*,17*R*)-12-*tert*-butyl-*N*-((1*R*,2*S*)-1-{[(cyclopropylsulfonyl)amino]carbonyl}-2-vinylcyclopropyl)-1,7,7-trimethyl-10,13-dioxo-3,6,7,8,10,11,12,13,16,17-decahydro-15*H*-14,17-methano-9,18-dioxo-2a,11,14,19-tetraazabenz[*g*]cyclononadeca[1,2,3-*cd*]indene-15-carboxamide,

(4*E*,14*S*,17*S*,19*R*)-14-cyclopentyl-*N*-((1*R*,2*S*)-1-{[(cyclopropylsulfonyl)amino]carbonyl}-2-vinylcyclopropyl)-1,9,9-trimethyl-12,15-dioxo-3,6,7,8,9,10,12,13,14,15,18,19-dodecahydro-17*H*-16,19-methano-11,20-dioxo-2a,13,16,21-tetraazabenz[*g*]cyclohenicosa[1,2,3-*cd*]indene-17-carboxamide,

(4*E*,14*S*,17*S*,19*R*)-14-cyclopentyl-*N*-((1*R*,2*S*)-1-{[(cyclopropylsulfonyl)amino]carbonyl}-2-vinylcyclopropyl)-1,11-dimethyl-12,15-dioxo-6,7,8,9,10,11,12,13,14,15,18,19-dodecahydro-3*H*,17*H*-16,19-methano-20-oxa-2a,11,13,16,21-pentaazabenz[*g*]cyclohenicosa[1,2,3-*cd*]indene-17-carboxamide,

(14*S*,17*S*,19*R*)-14-cyclopentyl-*N*-((1*R*,2*S*)-1-{[(cyclopropylsulfonyl)amino]carbonyl}-2-vinylcyclopropyl)-1,9,9-trimethyl-12,15-dioxo-3,4,5,6,7,8,9,10,12,13,14,15,18,19-tetradecahydro-17*H*-16,19-methano-11,20-dioxo-2a,13,16,21-tetraazabenz[*g*]cyclohenicosa[1,2,3-*cd*]indene-17-carboxamide,

(14*S*,17*S*,19*R*)-14-cyclopentyl-*N*-((1*R*,2*S*)-1-{[(cyclopropylsulfonyl)amino]carbonyl}-2-vinylcyclopropyl)-1,11-dimethyl-12,15-dioxo-4,5,6,7,8,9,10,11,12,13,14,15,18,19-tetradecahydro-3*H*,17*H*-16,19-methano-20-oxa-2a,11,13,16,21-pentaazabenz[*g*]cyclohenicosa[1,2,3-*cd*]indene-17-carboxamide,

(12*S*,15*S*,17*R*)-12-*tert*-butyl-*N*-((1*R*,2*S*)-1-{[(cyclopropylsulfonyl)amino]carbonyl}-2-vinylcyclopropyl)-1,7,7-trimethyl-10,13-dioxo-3,4,5,6,7,8,10,11,12,13,16,17-dodecahydro-15*H*-14,17-methano-9,18-dioxo-2a,11,14,19-tetraazabenz[*g*]cyclononadeca[1,2,3-*cd*]indene-15-carboxamide,

(4*E*,13*S*,16*S*,18*R*)-13-*tert*-butyl-*N*-((1*R*,2*S*)-1-{[(cyclopropylsulfonyl)amino]carbonyl}-2-vinylcyclopropyl)-22-methoxy-1,8,8-trimethyl-11,14-dioxo-6,7,8,9,11,12,13,14,17,18-decahydro-3*H*,16*H*-15,18-methano-10,19-dioxo-2a,12,15,20-tetraazabenz[*g*]cycloicosa[1,2,3-*cd*]indene-16-carboxamide,

(3*R*,5*S*,8*S*)-8-cyclopentyl-*N*-((1*R*,2*S*)-1-{[(cyclopropylsulfonyl)amino]carbonyl}-2-vinylcyclopropyl)-26-ethoxy-13,13-dimethyl-7,10-dioxo-2,11-dioxo-6,9,25-triazapentacyclo[15.10.2.1^{3,6}.0^{18,23}.0^{24,28}]triaconta-1(27),17,19,21,23,25,28-heptaene-5-carboxamide,

(3*R*,5*S*,8*S*)-8-cyclohexyl-*N*-((1*R*,2*S*)-1-{[(cyclopropylsulfonyl)amino]carbonyl}-2-vinylcyclopropyl)-18-methoxy-13,13-dimethyl-7,10-dioxo-2,11-dioxo-6,9,21,24-

tetraazapentacyclo[15.9.2.1^{3,6}.0^{20,27}.0^{21,25}]nonacosa-1(26),17,19,22,24,27-hexaene-5-carboxamide,

(3*R*,5*S*,8*S*)-8-cyclohexyl-*N*-((1*R*,2*R*)-1-{[(cyclopropylsulfonyl)amino]carbonyl}-2-ethylcyclopropyl)-18-methoxy-13,13-dimethyl-7,10-dioxo-2,11-dioxo-6,9,21,24-

5 tetraazapentacyclo[15.9.2.1^{3,6}.0^{20,27}.0^{21,25}]nonacosa-1(26),17,19,22,24,27-hexaene-5-carboxamide,

(3*R*,5*S*,8*S*)-8-cyclohexyl-*N*-((1*R*,2*S*)-1-{[(cyclopropylsulfonyl)amino]carbonyl}-2-vinylcyclopropyl)-13,13-dimethyl-7,10-dioxo-2,11-dioxo-6,9,21,24-

10 tetraazapentacyclo[15.9.2.1^{3,6}.0^{20,27}.0^{21,25}]nonacosa-1(26),17,19,22,24,27-hexaene-5-carboxamide,

or a pharmaceutically acceptable salt thereof.

14. A compound of any one of Claims 1 to 13 or a pharmaceutically acceptable salt thereof for use in therapy.

15

15. A compound of any one of Claims 1 to 13 or a pharmaceutically acceptable salt thereof for use in the treatment or prevention of infection by hepatitis C virus in a human or animal.

16. Use of a compound of any one of Claims 1 to 13, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for treatment or prevention of infection by hepatitis C virus in a human or animal.

20

17. A pharmaceutical composition comprising a compound of any one of Claims 1 to 13, or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable carrier.

25

18. The pharmaceutical composition as claimed in Claim 17 further comprising one or more other agents for the treatment of viral infections such as an antiviral agent, or an immunomodulatory agent such as α -, β - or γ -interferon.

19. A method of inhibiting hepatitis C virus protease and/or of treating or preventing an illness due to hepatitis C virus, the method involving administering to a human or animal subject suffering from the condition a therapeutically or prophylactically effective amount of the pharmaceutical composition claimed in Claim 17 or Claim 18 or of a compound of any one of Claims 1 to 13, or a pharmaceutically acceptable salt thereof.

35

INTERNATIONAL SEARCH REPORT

International application No

PCT/GB2008/050585

A. CLASSIFICATION OF SUBJECT MATTER

INV. C07K5/08 C07K5/12 A61K38/00 A61K31/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

C07K A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 2007/015855 A (MERCK & CO INC [US]; HOLLOWAY M KATHARINE [US]; LIVERTON NIGEL J [US];) 8 February 2007 (2007-02-08) cited in the application Claims	1-19
A	WO 2007/016441 A (MERCK & CO INC [US]; HOLLOWAY M KATHARINE [US]; LIVERTON NIGEL J [US];) 8 February 2007 (2007-02-08) cited in the application Claims	1-19
A	WO 2006/119061 A (MERCK & CO INC [US]; HOLLOWAY M KATHARINE [US]; LIVERTON NIGEL J [US];) 9 November 2006 (2006-11-09) cited in the application Claims	1-19
	----- -/-	

☒ Further documents are listed in the continuation of Box C.☒ See patent family annex.

* Special categories of cited documents:

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

& document member of the same patent family

Date of the actual completion of the international search

1 December 2008

Date of mailing of the international search report

10/12/2008

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040,
Fax: (+31-70) 340-3016

Authorized officer

Goss, Ilaria

INTERNATIONAL SEARCH REPORT

International application No

PCT/GB2008/050585

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X,P	WO 2008/057209 A (MERCK & CO INC [US]; ANGELETTI P IST RICHERCHE BIO [IT]; LIVERTON NIGE) 15 May 2008 (2008-05-15) claims 1,17	1-19
A	WO 2005/070955 A (BOEHRINGER INGELHEIM INT [DE]; BOEHRINGER INGELHEIM PHARMA [DE]; LLINA) 4 August 2005 (2005-08-04) the whole document	1-19
A	GOUDREAU N ET AL: "The Therapeutic Potential of NS3 Protease Inhibitors in HCV Infection" EXPERT OPINION ON INVESTIGATIONAL DRUGS, ASHLEY PUBLICATIONS LTD., LONDON, GB, vol. 14, no. 9, 1 January 2005 (2005-01-01), pages 1129-1144, XP003005098 ISSN: 1354-3784 the whole document	1-19

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/GB2008/050585

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 2007015855	A	08-02-2007	AR 057456 A1	05-12-2007
			AU 2006276189 A1	08-02-2007
			CA 2615022 A1	08-02-2007
			EP 1924593 A1	28-05-2008
			EP 1910404 A1	16-04-2008
			KR 20080027860 A	28-03-2008
			WO 2007015787 A1	08-02-2007
WO 2007016441	A	08-02-2007	AU 2006275605 A1	08-02-2007
			CA 2615896 A1	08-02-2007
			EP 1913016 A1	23-04-2008
			KR 20080036598 A	28-04-2008
WO 2006119061	A	09-11-2006	AU 2006242475 A1	09-11-2006
			CA 2606195 A1	09-11-2006
			EP 1879607 A2	23-01-2008
WO 2008057209	A	15-05-2008	NONE	
WO 2005070955	A	04-08-2005	AR 047444 A1	18-01-2006
			CA 2549851 A1	04-08-2005
			EP 1730167 A1	13-12-2006
			JP 2007534662 T	29-11-2007
			UY 28722 A1	31-08-2005